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ABSTRACT 
 
 
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) is a pyridoxal 5’-
phosphate (PLP)-dependent enzyme that catalyzes the first committed step of 
heme biosynthesis in animals, the condensation of glycine and succinyl-CoA 
yielding 5-aminolevuliante (ALA), CoA, and CO2. Murine erythroid-specific ALAS 
(mALAS2) variants that cause high levels of PPIX accumulation provide a new 
means of targeted, and potentially enhanced, photosensitization. Transfection of 
HeLa cells with expression plasmids for mALAS2 variants, specifically for those 
with mutated mitochondrial presequences and a mutation in the active site loop, 
caused significant cellular accumulation of PPIX, particularly in the membrane. 
Light treatment of HeLa cells expressing mALAS2 variants revealed that 
mALAS2 expression results in an increase in cell death in comparison to 
aminolevulinic acid (ALA) treatment producing a similar amount of PPIX. 
Generation of PPIX is a crucial component in the widely used photodynamic 
therapies (PDT) of cancer and other dysplasias. The delivery of stable and highly 
active mALAS2 variants has the potential to expand and improve upon current 
PDT regimes.  
Mutations in the C-terminus of human ALAS2 (hALAS2) can increase 
hALAS2 activity and are associated with X-linked erythropoietic protoporphyria 
(XLEPP), a disease phenotypically characterized by elevated levels or PPIX and 
xiii 
 
zinc protoporphyrin in erythroblasts. This is apparently due to enhanced cellular 
hALAS2 activity, but the biochemical relationship between these C-terminal 
mutations and increased hALAS2 activity is not well understood. HALAS2 and 
three XLEPP variants were studied both in vitro to compare kinetic and structural 
parameters and ex vivo in HeLa and K562 cells. Two XLEPP variants, delAGTG, 
and Q548X, exhibited higher catalytic rates and affinity for succinyl-CoA than 
wild-type hALAS2, had increased transition temperatures, and caused porphyrin 
accumulation in HeLa and K562 cells. Another XLEPP mutation, delAT, had an 
increased transition temperature and caused porphyrin accumulation in 
mammalian cells, but exhibited a reduced catalytic rate at 37°C in comparison to 
wild-type hALAS2. The XLEPP variants, unlike wild-type hALAS2, were more 
structurally responsive upon binding of succinyl-CoA, and adopted distinct 
features in tertiary and PLP cofactor-binding site. These results imply that the C-
terminus of hALAS2 is important for regulating its structural integrity, which 
affects kinetic activity and stability. 
XLEPP has only recently been identified as a blood disorder, and thus 
there are no specific treatments. One potential treatment involves the use of the 
antibiotic isonicotinic acid hydrazide (isoniazid, INH), commonly used to treat 
tuberculosis. INH can cause sideroblastic anemia as a side-effect and has 
traditionally been thought to do so by limiting PLP availability to hALAS2 via 
direct inhibition of pyridoxal kinase, and reacting with pyridoxal to form pyridoxal 
isonicotinoyl hydrazone. We postulated that in addition to PLP-dependent 
inhibition of hALAS2, INH directly acts on hALAS2. Using FACS and confocal 
xiv 
 
microscopy, we show here that INH reduces protoporphyrin IX accumulation in 
HeLa cells expressing either wild-type human hALAS2 or XLEPP variants. In 
addition, PLP and pyridoxamine 5’-phosphate (PMP) restored cellular hALAS2 
activity in the presence of INH. Kinetic analyses with purified hALAS2 
demonstrated non-competitive or uncompetitive inhibition with an apparent Ki of 
1.5 µM. Circular dichroism studies revealed that INH triggers structural changes 
in hALAS2 that interfere with the association of hALAS2 with its PLP cofactor. 
These studies demonstrate that hALAS2 can be directly inhibited by INH,  
provide insight into the mechanism of inhibition, and support the prospective use 
of INH in treating patients with XLEPP and potentially other cutaneous 
porphyrias. 
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CHAPTER 1: INTRODUCTION 
 
 
Biosynthesis of 5-aminolevulinate and heme 
 
Heme plays a central role in nearly all living organisms due to its vital 
functions in biological processes such as, respiration, gas sensing (1,2) and 
oxygen metabolism and transport (3). Heme also functions as an essential 
cofactor for cytochromes P450, catalases, and peroxidases (4). Heme 
biosynthesis begins with the condensation of succinyl-CoA and glycine, 
catalyzed by 5-aminolevulinate synthase (ALAS), to form 5-aminolevulinic acid 
(ALA) (5). The reaction proceeds as follows:  
 
Glycine + Succinyl-CoA  CoA + CO2 + ALA.  
 
In the final reactions of the pathway, protoporphyrinogen IX is oxidized to 
protoporphyrin IX (PPIX), into which ferrous iron (Fe2+) is inserted to form heme, 
a reaction catalyzed by ferrochelatase (Figure 1.1) (6,7). 
One molecule of heme is made from eight molecules of ALA, the common 
precursor to all naturally occurring tetrapyrroles, in either eight or nine enzymatic 
steps, depending on the organism (8). In nature, ALA is synthesized by two 
distinct routes. Mammals, fungi, and α-proteobacteria synthesize ALA from 
glycine and succinyl-CoA, via the C4 pathway, while in plants, archaea, and most 
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bacteria, ALA is synthesized from glutamyl-tRNA via the C5 pathway (Figure 
1.2). In all organisms except one, the photosynthetic phytoflagellate Euglena 
gracilis (9-13), production of ALA for tetrapyrrole synthesis is carried out by only 
one of these two pathways. 
The first evidence for the utilization of glycine as one of the initial 
precursors of heme was presented in 1945 by David Shemin when he infamously 
synthesized and then ingested 66g of 32% 15[N] glycine in addition to his usual 
diet (14). He observed that the isotopic nitrogen of glycine was incorporated in 
his blood’s heme, and he concluded that the nitrogen atoms of heme are derived 
from the NH3 group of glycine (14). The initial proposal that glycine represents 
one of the early precursors of heme was confirmed and expanded to animal 
subjects, demonstrating that among various amino acids, glycine was directly 
utilized as the predominant source for the nitrogen atoms of heme (15). It was 
evident that the nitrogen atoms of heme were derived from glycine, but there 
remained the question of to what extent glycine was utilized as a source for the 
heme carbon atoms. Altman et al. (16) demonstrated that only the α-carbon of 
glycine was incorporated into heme, whereas its carboxyl carbon was not (17). 
Thus, the carboxyl group of glycine had to be lost during some stage of heme 
synthesis.  
Since the α-carbon of glycine accounted for only 8 of the 32 carbon atoms 
of heme (18), the search for the potential substrate(s) other than glycine 
intensified. At this time, several groups suggested the involvement of an 
intermediate from the TCA cycle as a possible precursor of heme, with α-
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ketoglutarate as the most plausible candidate (18,19). However, Shemin and 
Wittenberg (20) proposed that the precursor used for heme formation was a four-
carbon, asymmetric compound, and therefore they rejected any direct 
involvement of α-ketoglutarate or succinate in heme biosynthesis. Their 
conclusion for the involvement of a four-carbon asymmetric compound was 
based on the observed isotopic distribution patterns of the individual carbon 
atoms in heme synthesized in the presence of labeled acetate. Briefly, heme was 
synthesized by incubating avian erythrocytes with acetate whose carboxyl group 
was labeled with 14C and by incubating with acetate whose methyl group was 
labeled with 14C (20). Following its synthesis and isolation, heme was degraded 
into individual chemical components in order to identify the positions of the 
isotopic carbon atoms. The observed isotopic distribution patterns of the 
individual carbons strongly argued against direct involvement of α-ketoglutarate 
or succinate in heme biosynthesis; instead, the isotopic distribution patterns 
suggested a four-carbon, asymmetric compound serving as the precursor for all 
the non-glycine-derived carbon atoms of heme (20). It was proposed that the 
four-carbon, asymmetric compound was most likely a succinyl-coenzyme 
complex derived from the TCA cycle (20), and the validity of this proposal was 
corroborated several years later with the observation that the synthesis of ALA in 
bacterial and avian extracts exhibited dependence on succinyl-CoA (21,22). 
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Figure 1.1. The heme biosynthetic pathway. Numbers designate individual enzyme-
catalyzed steps of heme biosynthesis and are as follows: 1) ALA synthase, 2) ALA 
dehydratase, 3) uroporphyrinogen synthase, 4) uroporphyrinogen-III cosynthase, 5) 
uroporphyrinogen decarboxylase, 6) coproporphyrinogen oxidase, 7) 
protoporphyrinogen oxidase, and 8) ferrochelatase. Abbreviations are as follows: ALA, 
5-aminolevulinate synthase; PBG, porphobilinogen; HMB, pre-uroporphyrinogen; 
UROIII, uroporphyrinogen III; COPROIII, coproporphyrinogen III; PPGIX, 
protoporphyrinogen IX; PPIX, protoporphyrin IX. 
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Figure 1.2. Biosynthesis of ALA via the C4 and C5 pathways. ALA is the common 
committed precursor to tetrapyrroles and is biosynthesized by two routes.  Plants and 
most bacteria synthesize ALA from glutamyl-tRNAGlu by reduction of glutamate to 
glutamate-1-semialdehyde.  This is then converted to ALA by glutamate-1-semialdehyde 
aminotransferase. Non-plant eukaryotes and the α-subclass of purple bacteria 
synthesize ALA by the C4 pathway, which requires the respiratory intermediate succinyl-
CoA. Euglena gracilis, an extraordinary unicellular organism with properties of both 
plants and animals, has the capacity to synthesize ALA by both pathways. 
 
5-Aminolevulinate Synthase 
There are two isoforms of ALAS expressed by two separate genes in 
animals (23). Human ALAS1, the housekeeping gene, is located on chromosome 
3p21 (24) and the first complete nucleotide sequence of ALAS1 was obtained 
using chick embryo liver (25), which represented the first complete nucleotide 
sequence of ALAS to be cloned from any source. After this initial report of the 
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full-length cDNA clone, Elliott and colleagues (26) proceeded to isolate the 
chicken ALAS gene and its putative control regions. The chicken ALAS gene 
spans 6.9 kb of DNA and alignment with the chick embryo cDNA sequence (25) 
shows that it is divided into 10 exons ranging from 156-280 bp, split by 9 introns 
of more variable length (26). The 10 exons contain 2103 nucleotides, which 
encode an ALAS precursor protein of 635 amino acids.  
ALAS2, the erythroid-specific gene, is located on the X-chromosome 
(23,24). The mouse ALAS2 gene consists of 11 exons and 10 introns, spanning 
approximately 24 kb (27). The first exon consists of 37 base pairs of non-coding 
sequence and is separated from the body of the gene by a 6 kb intron. 
Consistent with the similarity observed between the mouse ALAS2 cDNA 
sequence and the chicken ALAS1 sequence (25,28), the location of the 
intron/exon boundaries 3' of exon 3 are virtually identical in chicken ALAS1 (26). 
A notable difference is the absence of a distant and non-coding first exon in the 
chicken. Also, the chicken ALAS1 introns are generally more modest in size, as 
the chicken gene spans only 6.9 kb.  
Like mouse ALAS2, human ALAS2 also consists of 10 protein-coding 
exons and a 5’-untranslated exon (29) that contains sequence coding for an iron-
responsive element important for the regulation of mRNA translation (30,31). The 
human gene structure bears remarkable similarity to the mouse ALAS2 (27). An 
examination of the immediate promoter of the human ALAS2 gene by Cox et al. 
(30) revealed several interesting putative cis-acting motifs. Unlike that of the 
mouse erythroid ALAS gene, the human promoter contains a consensus TATA 
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box at position -27 and a consensus CCAAT box at position -87. Cox et al. (30) 
also identified a possible GATA-1 binding site located at position -100. At position 
-40 there is a perfect consensus for NF-E2, another erythroid-specific factor 
found in the promoter of the erythroid porphobilinogen deaminase (PBGD) gene 
(32,33) and upstream of β-globin (34-36).  
 
Regulation of ALAS2 Transcription 
 
ALAS1 and ALAS2 each have evolved distinct transcriptional regulatory 
processes, likely correlated with the stringent regulation necessary for the large 
heme requirement during erythropoiesis that is not required in non-erythroid cells 
(37). Hence, during erythropoiesis, transcription of all genes for ALAS2 and the 
other heme pathway enzymes and globin (38) are clearly up-regulated (39). 
Transcription of human ALAS2 is regulated by erythroid-specific transcription 
factors that act at the promoter and intronic enhancer sites (37,40), as well as 
downstream of the gene in the 3’-flanking region (41). In 1989, Schoenhaut and 
Curtis (27)  published the structure of the mouse ALAS2 gene and identified the 
DNAse I hypersensitivity sites. Since many enhancer-like sequences associated 
with other erythroid-specific sequences are marked by DNAse I hypersensitivity, 
in 1998 Surinya et al. (31,40) set out to determine whether the intronic 
sequences corresponding to DNAse I-hypersensitivity in the mouse ALAS2 gene 
play a role in human ALAS2 transcriptional regulation. The significance of introns 
1, 3, and 8 on ALAS2 expression were assessed by analysis of the effects of 
intron deletions, revealing that intron 3 is marginally inhibitory and introns 1 and 8 
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are stimulatory. Intron 8 conferred the strongest stimulation of promoter activity in 
K562 and MEL cells, and was found to be orientation-dependent. Specifically a 
239 bp region located within intron 8, which is highly conserved in the human, 
mouse, and dog ALAS2 genes, was identified as the region conferring enhancer 
activity. In K562 cells, a 25-fold level of stimulation was observed when the 
enhancer was located upstream of the promoter and oriented in the same 
direction as the promoter, while only a 4-fold increase was observed when the 
enhancer was in the reverse direction. In this region, two CACCC box binding 
sites and four GATA-1 binding sites were identified, and functional contributions 
were assessed through site-directed mutagenesis experiments and gel shift 
assays to determine binding of individual transcription factors. Mutational 
analysis demonstrated that the two CACCC boxes and one of the GATA motifs 
were functional. The CACCC boxes each bind Sp1, but not erythroid Krüppel-like 
factor (EKLF) or basic Krüppel-like factor (BKLF), and the GATA motif binds 
GATA-1 in vitro (40).  
In 2000, Kramer et al. (42) further examined the role of GATA-1 in the 
transcriptional regulation of murine ALAS2. They investigated the function of the 
5’-flanking region of the murine ALAS2 gene in erythroid and non-erythroid cells, 
as well as in erythroid cells chemically induced to undergo differentiation. 
Transient transfections of mammalian cell lines with different sections of the 
murine ALAS2 promoter indicated that the first 700 bp of the murine promoter 
were required to give maximal expression. Specifically, it was found that the first 
700 bp of the mouse ALAS2 promoter are essential for maximal expression in 
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murine erythroleukemia (MEL) cells and human myelogenous leukemia (K562) 
cells, although these regions stimulated similar expression in the human cervical 
carcinoma (HeLa) cells and mouse embryonic fibroblasts (NIH 3T3). 
Furthermore, in the mouse ALAS2 5’-flanking region, there are two critical GATA-
1 binding sites within the first 300 bp; however additional upstream cis-acting 
elements are also necessary for maximal transient transcriptional activation. A 
region located within -518 to -315 bp is crucial for transcriptional activation during 
the chemically induced differentiation of MEL cells. The GATA-1 interaction with 
the two GATA-1-binding sites in the proximal ALAS2 promoter, located at -118/-
113 and -98/-93, is also critical to confer erythroid cell specificity. This conclusion 
was supported both in vitro, by the elimination of GATA-1 binding upon mutation 
of either of the two GATA-1 elements using electrophoretic mobility shift assays 
(EMSA) and, in vivo, by the stimulation of the ALAS2 promoter activity of mutated 
GATA-1 binding sites-containing constructs in transiently transfected erythroid 
cells. 
Hypoxia indirectly affects heme production by inducing the erythropoiesis 
via erythropoietin and transferrin (43). Hypoxia-inducible factor 1 (HIF-1), 
originally identified as a nuclear factor that can bind to the human erythropoietin 
gene, plays a vital role in sensing and responding to hypoxia, but has also been 
shown to work through direct induction of ALAS2. HIF-1 is implicated in the 
transcriptional upregulation of erythropoietin (EPO), transferrin (44), and 
transferrin receptor (45), and thus leads to an increase of erythropoiesis and 
hematopoietic iron supply. There are two basic helix-loop-helix subunits that 
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compose HIF-1, HIF-1  and HIF-1 . HIF-1  is constitutively expressed, but 
rapidly degraded under normoxic conditions, while HIF-1  is both constitutively 
expressed and stable (46). Thus, it is the amount of HIF-1  that determines the 
overall HIF-1 level in a cell. HIF-1 functions by binding HIF-1-responsive 
elements in the 5’ regulatory regions of these genes and thereby mediating 
transcriptional activation. In 2000, Kramer et al. (42) identified a putative HIF-1-
responsive element (CACGTG) within the 5’-flanking region of the mouse ALAS2 
promoter at position -318 to -323. Since hypoxia induces several HIF-1 target 
genes involved in erythropoiesis, and ALAS2 is the rate-limiting enzymes in 
heme synthesis, in 2003 Hofer et al. (47) performed the first functional analysis of 
oxygen regulation of ALAS2. Nevertheless, despite an upregulation of ALAS2 
mRNA by hypoxia as expected, the putative HIF-1-binding site, located at -323/-
318 of the ALAS2 promoter, did not play a functional role. Thus, hypoxia 
induction of ALAS2 was concluded to be HIF-1-independent. 
However, in 2011, Zhang et al. (41) looked downstream of ALAS2 and 
identified three putative HIF-1-responsive elements located 611, 621, and 741 bp 
beyond the ALAS2-encoding region and within the 3’-UTR of the human ALAS2 
gene. They found that HIF-1 did bind to all three of the sites, overexpression of 
HIF-1  increased ALAS2 expression, and knockdown of HIF-1  by RNA 
interference decreased the level of ALAS2 expression. Thus, hypoxia results in a 
transcriptional upregulation of ALAS2 that is in fact HIF-1-dependent through 
HIF-1 binding sites downstream of the coding region of the ALAS2 gene (41). 
The hypoxic upregulation of ALAS2 expression contributed significantly to an 
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increased level of heme synthesis and likely represents an adaptive response to 
optimize heme biosynthesis under hypoxic conditions (41). Taken all together, 
evidence clearly supports that HIF-1 binds to elements in the 3’-flanking region of 
the human ALAS2 gene, and HIF-1 binding directly mediates the hypoxic 
induction of the human ALAS2 gene.  
It is well established that oxygen level plays a key role in systemic control 
of erythropoiesis through feedback regulation of EPO production, which is 
increased by tissue hypoxia and decreased by return to normoxia. However, it 
appears that hypoxia influences erythropoiesis beyond the known mechanism, in 
that red blood cell production is enhanced by low oxygen concentration at many 
stages of development. The actions caused by hypoxia on erythroid progenitors 
include enhanced amplification and acceleration of their proliferation, 
differentiation, and maturation (48). These effects are associated with a hypoxia-
induced gene expression profile, which includes increases in gene expression of 
ALAS2 in both cord blood and peripheral blood cell cultures, although increase is 
more prominent in cord blood cell cultures (48). GATA-1 expression is also 
increased by low oxygen in cord blood culture, and may be part of the 
mechanism linking ALAS2 expression to hypoxia. Globin expression is increased 
as well (48), which indicates that oxygen concentration is involved in the 
synchronization of heme and globin synthesis to efficiently generate hemoglobin. 
Sodium butyrate (NaBu) has also been shown to directly regulate ALAS2 
transcription. NaBu was first recognized to induce differentiation of 
erythroleukemic cells in 1975 by Leder et al. (49). In 2008, Han et al. (50) 
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examined the molecular basis underlying the NaBu activation of the ALAS2 
gene. They confirmed the effect of NaBu not only on transcriptional activation of 
ALAS2 in K562 cells, but also in the non-hematopoietic cell lines 293T human 
embryonic kidney epithelial cells and A549 human lung adenocarcinoma cells. 
They went on to identify Sp1 binding sites in the ALAS2 promoter that mediated 
responsiveness to NaBu activation, but that mutations of the GATA-1 sites did 
not affect ALAS2 activation by NaBu (50).  Furthermore, NaBu treatment led to 
an accumulation of Sp1 protein on the ALAS2 promoter, and it is speculated that 
histone deacetylase 1 (HDAC1) may be the target of NaBu inhibition that is 
responsible for ALAS2 expression (50). This is supported by previous work 
showing that the transcription cofactor p300 plays a role in ALAS2 transcription 
and activity of its histone acetyltranferase (HAT) is essential (51), and it was 
further shown that Sp1 and p300 synergistically upregulated ALAS2 expression, 
whereas HDAC1 reduced the synergy dose-dependently (50).  
MEL cells can be induced to undergo erythroid differentiation by a variety 
of agents including DMSO, hexamethylene bisacetamide (HMBA) and hemin (52-
57). The involvement of mitogen-activated protein kinases (MAPKs) in the 
regulation of erythroid differentiation has been studied in mammalian cell lines 
using these inducing agents (58-61) and demonstrates that MAPKs have an 
essential function in erythrocyte maturation. Both DMSO (52) and HMBA (53) 
increase ALAS2 expression in MEL cells. Treatment of HMBA-induced MEL cells 
with U0126, an extracellular-signal-related kinase (ERK) pathway inhibitor, 
further increases ALAS2 expression (62). In contrast, treatment with the p38 
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MAPK pathway inhibitor SB202190 slightly decreased ALAS2 expression over 
time (62). Thus, the ERK signaling pathway suppresses, and the p38 MAPK 
signaling pathways promotes the HMBA-induced erythroid differentiation of MEL 
cells. It is unclear how MAPKs are acting to control ALAS2 levels, but since 
MAPKs can function by regulating the activity of specific transcription factors 
through phosphorylation (63), they may be exerting effects through control of 
expression, DNA-binding, or transcriptional activity of transcription factors (62). 
 
Regulation of ALAS2 Translation  
 
Discovery of the intriguing properties of ferritin (64), a ubiquitous iron 
storage protein, stimulated many insightful studies that helped elucidate the 
major mechanisms for sensing and controlling cellular and organismal iron 
homeostasis. Initial studies demonstrated that ferritin abundance and synthesis 
were iron-responsive (65-67) and that mammalian cells contained a cytosolic iron 
sensor that controlled ferritin iron-responsive (65-67) and that mammalian cells 
contained a cytosolic iron sensor that controlled ferritin synthesis (68-70). In 
1976, the Munro and coworkers (71) demonstrated that iron stimulated ferritin 
synthesis by activating the translation of ferritin mRNAs. The next critical step in 
studies of ferritin expression involved the identification of an evolutionarily 
conserved 28 nucleotide sequence, termed the Iron-Responsive Element (IRE), 
which was present in the 5′-UTR of ferritin mRNAs. The IRE proved to be 
necessary and sufficient for iron-dependent control of ferritin mRNA translation 
(72-74). These observations occurred simultaneously with the discovery of 
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cytosolic iron-regulated RNA binding proteins, IRP1 and IRP2, which recognize 
the IRE in a sequence and structure specific manner (75,76). A comparison of 
the data on ferritin regulation with data on transferrin receptor 1 (TfR1) from Kühn 
and associates (77,78), who showed that TfR1 mRNA stability was iron-regulated 
and that the regulatory element responsible was present in the 3′-UTR, 
suggested the idea of a general post-transcriptional regulatory network 
controlling mammalian iron metabolism (79). Further, Klausner and colleagues 
(80) then established that IRE-dependent post-transcriptional control was central 
to the regulation of cellular iron metabolism in vertebrates (81,82). 
A standard IRE stem structure (Figure 1.3) consists of variable sequences 
that form base pairs of moderate stability, and folds into an α-helix that is 
distorted by the presence of a small bulge in the middle, caused by either an 
unpaired C residue or an asymmetric UGC/C bulge/loop (83). The loop at the top 
of this stem contains a conserved 5’-CAGUGX-3’ sequence, in which ”X” 
represents either an A, C, or U (83). This top loop most likely functions as a 
molecular ruler that orients and correctly distances the bulge C from residues in 
the loop, allowing flexible residues to participate in sequence-specific interactions 
between the IRE and IRPs (84).  
In 1991, examination of the immediate promoter of the human ALAS2 
gene revealed a putative IRE in the 5’-UTR of the human ALAS2 mRNA that is 
not present in the ALAS1 mRNA (30). This IRE motif was shown through gel 
retardation analysis to form a protein-RNA complex with cytosolic extracts from 
human K562 cells and this binding was strongly competed with IRE transcripts 
15 
 
from ferritin or transferrin receptor mRNAs (30). Furthermore, a transcript of the 
ALAS2 IRE mutated in the conserved loop of the IRE did not readily produce this 
protein-RNA complex in gel retardation analyses. These results supported that 
the IRE in the ALAS2 mRNA is indeed functional and that translation of the 
mRNA during erythropoiesis is regulated by the availability of cellular iron (30). It 
was also later confirmed by a separate group that the IRE motif contained in 
ALAS2 mRNA is sufficient to confer translational control to a reporter mRNA both 
in transfected MEL cells and in vitro (85). Thus, the level of cellular iron during 
erythropoiesis plays a significant role in dictating the translation of ALAS2 mRNA, 
and this occurs through the interaction with the IRE motif in ALAS2, a motif not 
present in ALAS1 mRNA. 
Considering that ALAS2 catalyzes the initial reaction for heme 
biosynthesis in erythroid cells, the translational repression of its mRNA by IRPs 
associates the IRE-IRP system with systemic iron utilization and homeostasis. 
This physiological response may be critical to inhibit the accumulation of toxic 
protoporphyrin IX when iron is scarce, as is illustrated by two disease 
phenotypes. Shiraz mutant zebrafish, which have a genetic defect in glutaredoxin 
5 (GLRX5), a gene required for Fe-S cluster assembly, exhibit severe 
hypochromic anemia, and show impairment to the regulation of IRP1 that 
eventually leads to the translational repression of ALAS2 (86). A comparable 
biochemical phenotype is seen in human patients with sideroblastic anemia in 
which ALAS2 mRNA translation is suppressed by both IRPs because the 
16 
 
deregulation of IRP1 was associated with cytosolic iron depletion and 
concomitant induction of IRP2 (87).  
 
 
Figure 1.3. The IRE located in the 5’-UTR of ALAS2 mRNA is a specific binding site 
for IRP and is sufficient to mediate iron-dependent translational regulation. The 
IREs found in (A.) murine ALAS2 mRNA and (B.) human ALAS2 mRNA. (C.) In the 
presence of iron, IRPs do not bind to the IRE, allowing for translation of ALAS2 mRNA. 
(D.) In iron-depleted cells, IRP binding to the IRE in the 5′-UTR interferes with 
translational initiation. 
 
 
In 2010, Ye et al. (87) hypothesized that transcriptional remodeling in 
response to cell stress may account for systolic iron depletion, which activates 
IRPs, repressing ALAS2 synthesis, and thus inhibiting heme synthesis in GLRX5 
deficiency. They found that in GLRX5-deficient cells, [Fe-S] cluster biosynthesis 
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was impaired and the IRE-binding activity was IRP1 was activated. Also, they 
observed increased IRP2 levels, indicative of relative cytosolic iron depletion, 
together with mitochondrial iron overload. Decreased ALAS2 levels attributable to 
IRP-translational repression were seen in erythroid cells in which GLRX5 
expression had been downregulated using siRNA (87). The IRE-IRP system and 
its ability to regulate heme synthesis via ALAS2 help to explain why GLRX5 
deficiency results in anemia in the zebrafish model and sideroblastic anemia in 
humans. 
 
Stability of ALAS2 
 
Regulation of ALAS2 at the protein level have been most notably studied 
in terms of oxygen level effects and also in terms of mutations seen in x-linked 
sideroblastic anemia (XLSA) patients. In 2005, Abu-Farha et al. (88) noted that 
ALAS2 contains a single, highly conserved LXXLAP sequence located at amino 
acid residues 515-520, that is not found in the corresponding sequence in ALAS1 
(Figure 1.4). This LXXLAP motif, where L is leucine, A is alanine, P is proline, 
and X is any amino acid, is a motif found in HIF1-α, which was previously 
discussed regarding its ability to upregulate ALAS2 transcription (41), is 
destabilized in normoxic conditions, leading to rapid hydroxylation, ubiquitination, 
and proteasomal degradation (89,90). A defining feature of this HIF-1  
degradation involves its two LXXLAP oxygen regulatory motifs, and its 
degradation process is known to be regulated through prolyl-4-hydroxlases that 
can hydroxylate the proline residues in the presence of oxygen, which leads to 
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ubiquitination of HIF1-α by E3 ubiquitin ligases (89-93). Through this LXXLAP 
motif, ALAS2 is regulated by hypoxia at the protein level and thus stabilized in 
low oxygen conditions much like HIF-1  (88). Not only is ALAS2 stabilized, but it 
is also more resistant to degradation under hypoxic conditions in comparison to 
normoxia. Mutation of proline 520 of the LXXLAP motif also caused stabilization 
of ALAS2 under normoxic conditions, suggesting that post-translational 
modification under normoxic conditions contributes to the degradation of ALAS2. 
Furthermore, mutation of proline 520 in vitro eliminated the ability of ALAS2 to be 
ubiquitinated in normoxic conditions (88). The mutation of proline 520 mimicked 
the lack of ubiquitination and stability of wild-type ALAS2 observed under hypoxic 
conditions. Thus, through its LXXLAP motif, ALAS2 can be stabilized under 
hypoxic conditions and resist ubiquitination and subsequent proteasomal 
degradation (88). 
 
 
 
Figure 1.4. Multiple alignment of ALAS2 and ALAS1 C-terminal amino acid 
sequences from multiple organisms. The LXXLAP motif is well-conserved in ALAS2, 
but not ALAS1. The extended C-terminus is not present in R. capsulatus ALAS, for 
which there is the only solved crystal structure of ALAS, and thus the tertiary structure of 
the extended C-terminus is unknown.  
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Another noteworthy region of ALAS2 is within the C-terminus of ALAS2, of 
which the final 33 amino acids are conserved in higher eukaryotes, but are not 
present in prokaryotes (Figure 1.4). Since the only crystal structure of ALAS2 that 
has been solved is of R. capsulatus (94), the tertiary structure of the C-terminus 
remains a mystery. However, it appears that the ALAS2 C-terminus may have a 
function in higher eukaryotes, as mutations in ALAS2 corresponding to the C-
terminus have been associated with both XLSA and x-linked erythropoietic 
porphyria (XLEPP) (95-97). In 2012, Kadirvel et al. (97) studied novel missense 
mutations in the 11th exon of the human ALAS2 gene associated with XLSA 
along with a human ALAS2 variant with a complete deletion of its C-terminus. 
Using a combination of experiments measuring in vitro enzymatic activity using 
bacterially expressed recombinant proteins and in vivo experiments evaluating 
catalytic activity by comparing the accumulation of porphyrins in eukaryotic cells 
stably expressing mutant ALAS2 enzyme tagged with FLAG, they concluded that 
the C-terminus of the human ALAS2 protein acts as an intrinsic regulator of 
catalytic activity and protein stability (97). Although there has been speculation of 
allosteric regulation, potentially through binding of iron or heme at a particular 
conserved “C-X-X-C” motif (98), and speculation of the potential for post-
translational modifications in the C-terminus (98), it is still unclear how the C-
terminal region is able to suppress the enzymatic activity, and how mutations in 
the C-terminus can cause changes in that activity and the stability of the enzyme.  
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Mitochondrial Import of ALAS2 
In mammalian cells, anabolic and catabolic pathways are normally 
confined to a single cellular compartment unless the process involves import or 
export of products or substrates. The tetrapyrrole biosynthetic pathway is 
atypical, as its first step and its last three steps are catalyzed by mitochondrial 
enzymes, whereas the intermediate four steps are catalyzed by cytosolic 
enzymes (99). All eight of the pathway enzymes are encoded in the nucleus and 
are synthesized in the cytosol with the mitochondrially located proteins being 
post-translationally translocated to their appropriate mitochondrial space. For 
example, coproporphyrinogen oxidase is located in the space between the inner 
and outer mitochondrial membranes (100,101), protoporphyrinogen oxidase is 
thought to be either in the space between the inner and outer mitochondrial 
membranes or associated with the matrix side of the inner mitochondrial 
membrane (102), and ferrochelatase is associated with the matrix side of the 
inner mitochondrial membrane (103). ALAS is located in the mitochondrial matrix 
where its substrates, glycine and succinyl-CoA, are found (31,104). A pre-
enzyme of ALAS is synthesized by cytosolic ribosomes, which is then imported to 
and processed within the mitochondria to yield the mature form of the enzyme 
(105-107). This pre-enzyme ALAS has a mitochondrial import sequence on its N-
terminus that is vital for recognition by the protein import machinery located in the 
mitochondrial membrane (108).  
Most mitochondrial proteins are encoded in the nucleus and synthesized 
in the cytosol as precursor polypeptides, larger than the corresponding mature 
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forms due to the additional amino-terminal residues comprising leader peptides. 
These precursor proteins are post-translationally recognized by mitochondria, 
translocated across one or both mitochondrial membranes by an energy-
dependent mechanism, and processed to their mature size by proteolytic 
removal of the amino-terminal leader peptides (109,110). The leader peptides 
are required for mitochondrial import, supported by the fact that precursors 
incubated with isolated mitochondria are imported, whereas the corresponding 
mature proteins either fail to be taken up or interfere with uptake of the 
precursors (110,111). Whether leader sequences function independently or in 
concert with sequences in the mature portions of the precursors was unknown 
until 1985, when Horwich et al. (112) demonstrated that the leader peptide is 
sufficient to direct mitochondrial import. Researchers employed gene fusion 
techniques to join the coding sequence of the precursor of the mitochondrial 
matrix enzyme ornithine transcarbamylase with the coding sequencing for the 
cytosolic enzyme dihydrofolate reductase. They showed that the chimeric protein 
was recognized by mitochondria, translocated by mitochondria, and 
proteolytically processed (112). Since this discovery, the mitochondrial import 
field has expanded significantly and become more complex than previously 
imagined, including the characterization of several classes of precursor proteins 
containing distinct targeting signals that are directed to different import routes 
(113). However, mitochondrial import facilitated by an amino-terminal 
presequence on the cytosolic protein remains the most recognized means of 
mitochondrial protein targeting, and it is by this method that ALAS is imported to 
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the mitochondria. 
Human ALAS2 is synthesized as a precursor of molecular mass 65 kDa 
with an amphipathic presequence of 49 amino acids (114). In general, 
mitochondrial presequences do not share any primary sequence identity (108), 
but they do show a statistical bias of positively charged amino acid residues, 
provided mostly through arginine residues (115). The positive charges in the 
presequences have the potential to interact with the negatively charged surface 
of mitochondrial membranes (116), the mitochondrial import receptor (117), and 
the mitochondrial processing peptidase (118,119). Mitochondrial leader 
sequences also share an ability to form an amphiphilic, α-helix (115,120,121). As 
much of heme synthesis depends on proper translocation of the enzymes active 
in the mitochondria, the mechanism of mitochondrial import of ALAS has been 
investigated in great detail, especially in terms of a role for feedback inhibition by 
heme. 
 
Heme Inhibition of ALAS Mitochondrial Import 
Researchers of ALAS in the 1960s and 1970s noted that the intracellular 
concentration of ALAS1 is normally low (122), but that an extensive selection of 
xenobiotics and steroids significantly increase its activity in mammalian (123) and 
avian liver cells (122,124-126), and cause the synthesis of high concentrations of 
porphyrins (127). Granick and Urata (122) produced chemically-induced 
porphyria in chick embryo liver cells that resembled human acute intermittent 
porphyria biochemically and noted that a number of chemical inducers are known 
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to precipitate attacks of the disease in susceptible individuals. Immunological 
studies later showed that, in experimentally induced porphyria, the synthesis of 
ALAS occurs de novo (128) and heme, the final product of the pathway, inhibits 
enzyme induction (125-127,129).  
Although there was a general agreement that heme plays an important 
role in the physiological control of ALAS activity (126,127,129,130), there was no 
such consensus on the mechanism of its action, and many different schemes 
were suggested. Granick (127) originally proposed that heme acts as a co-
repressor for ALAS transcription, and that chemical inducers acted as heme 
analogues that compete for the repressor protein, thus preventing heme from 
repressing ALAS mRNA transcription (127). However, later studies by Sassa and 
Granick (131) and Tyrrell and Marks (129) suggested that, contrary to this 
transcriptional theory, heme exerted its effect at a post-transcriptional stage. The 
finding that there was apparently no concentration-dependent competition 
between heme and porphyria-inducing chemicals (124,131) further argued 
against the original concept of Granick (127). The groups of Ohashi and Kikuchi 
(130) and Hayashi et al. (132) proposed that, in adult chickens, heme exerts its 
effect by controlling transport of cytoplasmically synthesized ALAS into the 
mitochondria. However, heme did not affect ALAS transport in embryonic chick 
liver (126,129,131).  
In 1980, Srivastava et al. (133,134) reevaluated the effects of heme on 
ALAS induction by using a newly developed system of isolated chick-embryo 
liver cells. In this system, they showed that initiation of ALAS induction requires 
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the presence of a chemical inducer, in this case 2-allyl-2-isopropylacetamide, but 
that continued presence of this inducer was not necessary, provided heme 
synthesis is prevented. This was compatible with a scheme in which 2-allyl-2-
isopropylacetamide causes a depletion of intracellular heme, and in which heme 
is the principal controlling agent in the induction of ALAS. Their data conflicted 
with those of Tyrrell and Marks (129) and showed that, at a concentration of 20 
nM, hemin will completely inhibit ALAS induction and that this effect is primarily 
at the level of transcription.  
Furthermore, Sassa and Granick (131) had estimated that the intracellular 
concentration of heme in chick embryo liver cells is in the order of 50-100 nM, 
which was sufficient to completely inhibit ALAS synthesis and to prevent 
induction of hepatic porphyria. At this time, the conclusion was that in chick-
embryo liver cells, induction of ALAS synthesis was being primarily regulated by 
the intracellular concentration of heme and that the effect of heme on the 
synthesis of ALAS is at the level of transcription. Also, they felt that translational 
effects seen at higher concentrations were more likely related to heme toxicity. 
However, through the discovery of a short amino acid sequence to which heme 
binds, termed a heme regulatory motif (HRM), scientists were able to specifically 
examine effects of heme on transport of precursor ALAS into the mitochondria 
(105,135,136). 
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Heme Regulatory Motifs of ALAS 
Both precursor ALAS1 and ALAS2 in mammals each contain three heme-
binding HRMs consisting of CP-based short amino acid sequences (Figure 1.5) 
(137), a motif found in many proteins and shown to function as heme-oxygen 
sensors in bacteria (138), yeast (139,140), and mammals (136,141,142). The 
HRMs in ALAS were initially identified to contain the sequence R/L/N-C-P-
L/V/I/F-L/M, where the cysteine and proline residues are invariable (136), 
although some minor substitutions are present in some species (143). Two of 
these motifs are contained in the region of the leader sequence that is 
proteolytically removed in the mitochondria, and the third is contained in the N-
terminus of the mature enzyme (Figure 1.6). In human ALAS1, the motif locations 
are referred to by their cysteine residues and are at amino acid positions C8, 
C33, and C108.  On the basis of in vitro translocation experiments with isolated 
mitochondria and ALAS2 protein, the two heme-binding motifs in the leader 
sequence have been proposed to bind heme and prevent translocation of  
precursor ALAS2 into the mitochondrion (136). Dailey et al. (144) studied the 
putative roles of all three HRMs in human ALAS1 in mitochondrial import, 
revealing both that each of the motifs play an independent functional role as a 
heme sensor, and that the HRMs function synergistically to achieve maximal 
heme inhibition. They demonstrated, through a collection of cysteine to serine 
mutations in human ALAS-GFP expressed in murine hepatoma cells, that 
intracellular translocation of ALAS1 is heme-sensitive and that this sensitivity is 
dependent on the presence of at least one of the heme-binding motifs. They had 
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not expected the third HRM located in the mature protein to be functional due to 
its distance, over 50 amino acid residues, from the targeting sequence. They 
hypothesized that given that little heme is present in the mitochondrial matrix 
compartment, it is plausible that any regulatory role for this particular HRM would 
be for translocation and not for enzyme inhibition or inhibition of cofactor binding  
 
 
Figure 1.5. The N-terminal amino acid sequence of human ALAS1 and ALAS2 
indicating the location of the HRMs. In human ALAS2, shown in black, the three 
HRMs, shown in bolded red, are located at C11, C38, and C70. In human ALAS1, 
shown in blue, HRMs are located at C8, C33, and C108. The N-terminus is the least 
similar domain between ALAS1 and ALAS2. 
 
 
by the precursor protein. Furthermore, it may be that the binding of heme at this 
site prevents the protein from folding properly, which would make it more 
susceptible to proteolytic processing in the cytoplasm (144). 
Lathrop and Timko (136) were the first to show that the conserved 
cysteines of the HRMs in murine ALAS2 are involved in heme inhibition of 
transport into the mouse mitochondria. In mouse ALAS2, the motif locations are 
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at amino acid positions C11, C38, and C70. In Lathrop and Timko’s initial 
experiments, the deletion of the third HRM (C70) that is normally present in N-
terminus of the mature form of ALAS2 did not significantly affect mitochondrial 
transport, and thus they continued experimentation of only the C11 and C38 
HRMs. Since conserved cysteine residues are often involved in the coordination 
of heme to its apoprotein (145,146), they mutagenized the C11 and C38 residues 
to serines and evaluated the effects of various hemin concentrations up to 25 μM 
on mitochondrial transport. Using hemin concentrations of 10 μM and 25 μM, 
they found that mutations of cysteines at both sites completely eliminated the 
heme inhibition of transport, while mutation of only either C11 or C38 resulted in 
a 75 to 82% inhibition of transport using 25 μM of hemin (136).  
  Goodfellow et al. (114) reinforced the functional role of the HRMs in 
ALAS2 by providing the structural data demonstrating that a heme-peptide 
interaction occurs between hemin and the presequence of murine ALAS2. 
However, some discrepancies on the functional role of the HRMs in ALAS2 still 
exist.  In 2004, Munakata et al. (147) compared the role of the HRMs in the 
heme-regulated transport of the ALAS1 and ALAS2 in vivo. They constructed a 
series of mutants of rat ALAS1 with mutated cysteines and expressed the 
constructs in quail QT6 fibroblasts through transient transfection to examine 
mitochondrial import of the enzymes in the presence of hemin (147). While they 
found both that hemin inhibited the mitochondrial import of wild-type ALAS1 and 
that this inhibition was reversed by the mutation of all three HRMs in the enzyme, 
exogenous hemin did not affect the mitochondrial import of the ALAS2 under the  
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Figure 1.6. Depiction of human ALAS1 and ALAS2 protein domains. Region A 
represents the presequence, region B represents the catalytic core domain, and region 
C represents the mature mitochondrial protein. The dotted lines represent the locations 
of the three HRMs in the respective ALAS proteins. In the entire precursor protein, 
56.2% of the amino acid residues are identical. However, the sequences are more 
similar in their catalytic core regions, in which 72.2% of amino acids are identical. The 
presequence is the most variable region of amino acid sequence. 
 
 
same experimental conditions (147). The differences between ALAS1 and 
ALAS2 may be attributed to the difference in their biological roles, observing that 
it may be the activity of ALAS1 is regulated through the inhibition of mitochondrial 
import by the intracellular concentration of heme, whereas the activity of ALAS2 
is mainly regulated translationally by the intracellular concentration of iron. 
Addtionally, free heme in erythroid precursors may never reach high enough 
concentrations to be able to inhibit mitochondrial import of ALAS2, since most 
heme molecules are bound to globin. In conclusion, the ability of heme to control 
mitochondrial import is well established for ALAS1, but heme inhibition on 
mitochondrial import for ALAS2 remains controversial. 
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Diseases associated with mutations in ALAS2 
Although there are no known genetic diseases associated with a mutation 
in the gene encoding ALAS1, there are two disease states associated with 
mutations in the gene encoding ALAS2—XLSA, the most common inherited 
sideroblastic anemia (148), and XLEPP (96). In XLSA, there is a decreased 
function of the ALAS2 enzyme. XLSA is characterized by anemia, which is a lack 
of healthy erythrocytes, and iron accumulation in perinuclear mitochondria of 
erythroblasts in the bone marrow, called ring sideroblasts, which are present as a 
result of impaired iron utilization (95,149). The first case of microcytic, 
hypochromic anemia with an X-linked pattern of inheritance was described in 
1945 (150),  but it was not until 1992 that Cotter et al. (151) established that the 
genetic basis for XLSA lies on ALAS2 genetic mutations. While, as expected, 
XLSA predominantly affects males, females are also affected when the mutant 
allele is expressed as a result of lyonization (152).  
Management of XLSA symptoms involves not only treatment of anemia, 
but also prevention and treatment of iron overload (153). Approximately 75% of 
XLSA patients have mutations in ALAS2 that affect its binding to its PLP cofactor. 
These patients, termed pyridoxine-responsive, can be placed on a pyridoxine 
regimen to improve the function of the ALAS2 (152,153). Iron overload is treated 
based on the severity of the anemia. If the anemia is mild, then regular 
phlebotomies are performed as a preventive measure against iron overload; 
however, if the anemia is severe, then iron chelating agents, such as 
deferoxamine, are the preferred treatment (152). 
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In contrast to XLSA, XLEPP in characterized by an increase in function of 
the ALAS2 enzyme (96). These gain-of-function mutations result in an increase 
of PPIX in the bone marrow and circulating erythrocytes, and cause extreme 
skin photosensitivity. However, XLEPP was only recently identified because the 
symptoms of XLEPP are nearly identical to those of erythropoietic porphyria 
(EPP), which is caused by mutations in ferrochelatase that impair its function. 
Discovery of mutations in ALAS2 leading to porphyria demonstrated the 
association of each of the eight enzymes of heme biosynthesis with a unique 
porphyria (Table 1.1).  Acute porphyrias, also known as hepatic porphyrias, 
primarily affect the nervous system. Cutaneous porphyrias, also called 
erythropoietic porphyrias, primarily affect the skin resulting in 
photosensitivity.The biochemical distinction between XLEPP and EPP that 
ultimately led to the discovery of XLEPP is the accumulation of zinc-
protoporphyrin in red blood cells of XLEPP patients, an increase not seen in 
EPP patients (96). The high zinc-protoporphyrin concentrations can be 
explained considering that ferrochelatase can use Zn(II) as an alternate metal 
ion substrate (154), and the overactive ALASs present in XLEPP create an 
imbalance in the ratio of Fe(II) to protoporphyrin. Due to the substrate 
stoichiometric mismatch, Zn(II) is incorporated into protoporphyrin (155). Thus, 
measurement of zinc-protoporphyrin levels is the key for diagnosis of XLEPP. 
All mutations that have been characterized from patients with XLEPP are 
located at the C-terminus of the ALAS2 mature protein, which is highly 
conserved in mammals, implying that the C-terminal region of ALAS plays a vital 
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role in its regulation, activity, and /or stability. The increased catalytic efficiencies 
and substrate affinities of purified, recombinant human ALAS2 variants 
harboring some of the known XLEPP mutations versus those of wild-type ALAS2 
were consistent with the proposal that the XLEPP mutations in ALAS2 produced 
enzyme variants more active than ALAS2 in healthy individuals (156,157). In 
addition, the identification of a C-terminal, 33-amino acid sequence as the 
minimal size domain contributing to the gain-of-function of ALAS2 (156,158) 
supports the previously proposed molecular mechanism for the control of ALAS 
activity (98). However, the mechanism by which mutations in the C-terminus 
result in increased ALAS2 activity have yet to be fully elucidated. 
 
 
Table 1.1. Genes encoding heme biosynthesis enzymes implicated in inherited 
porphyrias. 
 
Gene Porphyria Classification 
ALAS2 X-linked erythropoietic protoporphyria (XLEPP) Cutaneous 
ALAD ALA dehydratase deficient porphyria (ALAD-P) Acute 
HMBS Acute intermittent porphyria (AIP) Acute 
UROS Congenital erythropoietic porphyria (CEP) Acute 
UROD Porphyria cutanea tarda (PCT) Cutaneous 
CPOX Hereditary coproporphyria (HCP) Cutaneous 
PPOX Variegate porphyria (VP) Acute 
FECH Erythropoietic protoporphyria (EPP) Cutaneous 
 
Content of this dissertation 
 This dissertation focuses on mutations in ALAS2 that lead to an increased 
activity of the enzyme. First, we evaluate whether mALAS2 variants with 
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increased activity could be useful for production of the photosensitizer PPIX for 
PDT. Secondly, to understand the mechanisms behind the symptoms of XLEPP, 
XLEPP variants with mutations in the ALAS2 C-terminus are characterized in 
terms of their catalytic activity, substrate affinities, thermostability, cellular 
activity, and structure. Thirdly, INH, an antibiotic used to treat tuberculosis, is 
evaluated as an inhibitor for human ALAS2. The conclusions presented in each 
chapter add to the general knowledge of the ALAS-catalyzed reaction, provide 
insight into the mechanism of XLEPP, and provide evidence for INH as an 
inhibitor of ALAS2, which has potential for treating porphyria patients. 
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CHAPTER 2: EXPRESSION OF MURINE 5-AMINOLEVULINATE SYNTHASE 
VARIANTS CAUSES PROTOPORPHYRIN IX ACCUMULATION AND  
LIGHT-INDUCED CELL DEATH IN MAMMALIAN CELLS 
 
 
Abstract 
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) catalyzes the first 
committed step of heme biosynthesis in animals.  The erythroid-specific ALAS 
isozyme (ALAS2) is negatively regulated by heme at the level of mitochondrial 
import and, in its mature form, certain mutations of the murine ALAS2 active site 
loop result in increased production of protoporphyrin IX (PPIX), the precursor for 
heme. Importantly, generation of PPIX is a crucial component in the widely used 
photodynamic therapies (PDT) of cancer and other dysplasias. ALAS2 variants 
that cause high levels of PPIX accumulation provide a new means of targeted, 
and potentially enhanced, photosensitization. In order to assess the prospective 
utility of ALAS2 variants in PPIX production for PDT, K562 human 
erythroleukemia cells and HeLa human cervical carcinoma cells were transfected 
with plasmids encoding ALAS2 variants with greater enzymatic activity than the 
wild-type enzyme. The levels of accumulated PPIX in ALAS2-expressing cells 
were analyzed using flow cytometry with fluorescence detection. Further, cells 
expressing ALAS2 variants were subjected to white light treatments (21-22 kLux) 
for 10 minutes after which cell viability was determined. Transfection of HeLa 
cells with expression plasmids for murine ALAS2 variants, specifically for those 
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with mutated mitochondrial presequences and a mutation in the active site loop, 
caused significant cellular accumulation of PPIX, particularly in the membrane. 
Light treatments revealed that ALAS2 expression results in an increase in cell 
death in comparison to aminolevulinic acid (ALA) treatment producing a similar 
amount of PPIX. The delivery of stable and highly active ALAS2 variants has the 
potential to expand and improve upon current PDT regimes.  
 
Introduction 
The first committed step of heme biosynthesis in non-plant eukaryotes and 
some prokaryotes, the pyridoxal 5’-phosphate (PLP)-dependent condensation of 
glycine and succinyl-coenzyme A to generate 5-aminolevulinate (ALA), 
coenzyme A (CoA), and CO2, is catalyzed by 5-aminolevulinate synthase (ALAS) 
(1,2). This reaction is directly coupled to the citric acid cycle via the substrate 
succinyl-CoA and is the key regulatory step of heme biosynthesis (3). In 
mammals, two chromosomally distinct genes each encode an ALAS isoenzyme, 
and the two isoenzymes are differentially expressed in a tissue specific manner 
(4).  The human gene for the non-specific or housekeeping isoform, ALAS1, is 
located on chromosome 3 (5,6), and is expressed ubiquitously in all tissues (7). 
The gene encoding the erythroid specific isoform, ALAS2, is located on the x-
chromosome (6,8) and is expressed only in developing erythroblasts (7). 
 
The two ALAS isoenzymes are translated as precursor proteins with N-
terminal mitochondrial matrix import signal sequences that are proteolytically 
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cleaved following importation to yield the mature enzymes (9-12).  The activity of 
the enzyme is only manifested upon localization to the mitochondrial matrix, as 
this is where the substrate succinyl-CoA is produced (13-16). An important 
aspect of the import sequences in both ALAS1 (17) and ALAS2 (18) are the 
presence of heme-regulatory motifs (HRMs), which consist of short amino acid 
sequences characterized in part by adjacent cysteine-proline (CP) residues (19). 
HRMs confer heme-binding properties and have been shown to function as 
heme-oxygen sensors in bacteria (20), yeast (21) and mammals (18,22,23). In in 
vitro translocation experiments with isolated mitochondria and ALAS2 precursor 
protein, the two heme-binding motifs in the leader sequence, corresponding to 
C11 and C38 in murine ALAS2 (mALAS2), were reported to bind heme and 
prevent translocation of precursor ALAS2 into the mitochondrion (18). Structural 
and biochemical data have also demonstrated that a heme-peptide interaction 
occurs between hemin and the presequence of ALAS2 (24), further indicating the 
potential of heme to act as a feedback inhibitor of the pathway by preventing the 
mitochondrial import of precursor ALAS2 when heme levels are sufficient for 
cellular requirements. 
Much of what we know about the chemical and kinetic mechanisms of 
ALAS2 comes from in vitro enzymatic assays that have helped establish and 
define the microscopic steps of the ALAS-catalyzed reaction, including the rates 
of glycine and succinyl-CoA binding, formation of the quinonoid intermediates, 
and product release (2,25-28). These studies, performed using mALAS2 purified 
from E. coli cells expressing the recombinant mature enzyme, have led to an 
59 
 
understanding of the importance of specific regions and single amino acid 
residues in the intrinsic activity of ALAS2 (29-35). Generally, a mutation made to 
an amino acid predicted to be of functional importance causes a decrease in 
activity of the enzyme. For example, K313 of mALAS2 was identified as the 
amino acid involved in the Schiff base linkage with the PLP cofactor (36), and 
mutations in K313 completely abolish measurable activity of mALAS2 under 
standard assay conditions (29,37). However, some mutations in mALAS2 cause 
significantly increased activity of the enzyme, as demonstrated both using 
purified enzyme (31,35), and in bacteria when expressing plasmids encoding the 
variant enzymes (35). These mutations are all located in an extended 
conformation region termed the active site loop (Y422-R439), which is predicted 
to act as a “lid” over the active site following substrate binding (35). Thus, ALAS 
is thought to undergo a conformational change from an open conformation, in 
which the substrates glycine and succinyl-CoA can bind in the active site, to a 
closed conformation, during which the products ALA, CoA, and CO2 are formed 
(25,28). When the reaction is complete, the active site loop reopens, and the 
products are released. It is the opening of the active site loop to allow product 
release that limits the overall rate of the enzymatic reaction (2,25,27). Based on a 
combination of kinetic (25,28) and structural modeling studies (38), it was 
proposed that mutations in the active site loop can lead to hyperactive forms of 
ALAS, defined as those with at least a 10-fold increase in catalytic efficiency 
toward one or both substrates, by accelerating reversion to the open loop 
conformation upon product formation (35). 
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Since ALAS catalyzes the rate-determining step of tetrapyrrole 
biosynthesis in mammals (2,25), overexpression of ALAS in prokaryotic (35) and 
eukaryotic cells (39) results in accumulation of the photosensitizing heme 
precursor, protoporphyrin IX (PPIX). This property has potential for applications 
of ALAS or ALAS variants in photodynamic therapy of tumors and other non-
malignant dermatological indications, such as acne vulgaris, psoriasis, and 
scleroderma (40,41). In this study, we transfected mammalian cells with mALAS2 
variants and measured PPIX accumulation using fluorescence activated cell 
sorting (FACS). We identified the R433K variant with additional mutations of the 
HRMs in the presequence as the variant causing the most cellular PPIX 
accumulation. Subsequently, we used the variants causing the most PPIX 
accumulation to study the cell death caused by the PPIX toxicity and 
photosensitization. 
 
Materials and Methods 
Materials—5-Aminolevulinic acid hydrochloride (ALA) was purchased from 
Acros Organics (Morris Plains, NJ), and dissolved in distilled water at a 
concentration of 10 mg/mL. Glycine, purchased from Fisher Chemical (Fairlawn, 
NJ), was dissolved in phenol red-free culture medium purchased from Mediatech, 
Inc. (Manassas, VA) to give a stock concentration of 1 M. Paclitaxel (6 mg/mL 
stock in DMSO) was graciously provided by the laboratory of Dr. Scott Antonia 
(H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL), and was 
diluted in culture medium directly before use. Deferoxamine mesylate, purchased 
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from Sigma (St. Louis, MO), was dissolved in distilled water to create a 10 mM 
stock solution. Propidium iodide, 4′,6-diamidino-2-phenylindole (DAPI) and 
kanamycin sulfate were purchased from Acros Organics (Morris Plains, NJ), and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was 
purchased from Sigma-Aldrich (St. Louis, MO). BmtI and BamHI restriction 
enzymes were obtained from New England BioLabs, Inc. G418 sulfate was 
procured from Mediatech, Inc. (Manassas, VA). 
 
Plasmids—The precursor ALAS2 cDNAs were individually subcloned into 
the multiple cloning site of the pIRES2-ZsGreen1 vector (purchased from 
Clontech Laboratories, Inc. Mountain View, CA) using the BmtI and BamHI 
restriction sites. Digested ALAS2-encoding fragments were ligated into the 
digested pIRES2-ZsGreen1 vector using T4 DNA ligase and ligase buffer 
(Thermo Scientific Fermentas (Waltham, MA)). Electrocompetent BL21(DE3) 
cells were transformed by electroporation with the ligated plasmid DNA and 
selected by spreading them on LB agar medium containing 10 g/mL kanamycin 
sulfate. Plasmid DNA was purified from a single colony using a QiaPrep Spin 
Miniprep kit (Qiagen Inc.; Germantown, MD), and the sequence of the cloned 
DNA was verified by Genewiz, Inc. (New Brunswick, NJ).   
 
Cell culture—K562 human immortalized myelogenous leukemia cells 
(ATCC) were maintained in RPMI-1640 culture medium, purchased from 
Mediatech, Inc. (Manassas, VA), with 10% fetal bovine serum (FBS; purchased 
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from Thermo Scientific Waltham, MA), gentamicin (50 g/mL), penicillin (60 
μg/mL) and streptomycin (100 g/mL) at 37°C in a humidified incubator with 5% 
CO2. HeLa human cervical carcinoma cells (ATCC) were maintained in DMEM 
culture medium with 4.5 g/L glucose, L-glutamine, and sodium pyruvate 
(Mediatech, Inc.; Manassas, VA), with 10% fetal bovine serum (FBS), gentamicin 
(50 μg/mL), penicillin (60 μg/mL) and streptomycin (100 g/mL) at 37°C in a 
humidified incubator with 5% CO2.  
 
Stable transfection of K562 human erythroleukemia cells—K562 cells 
were transfected with Lipofectamine™ LTX and PLUS™ Reagent, purchased 
from Invitrogen (San Jose, CA), according to the supplier’s optimized protocol for 
K562 cells. On the day of transfection, a hemocytometer and trypan blue staining 
were used to count the cells and determine culture density and viability. In a 6-
well plate, K562 cells (5 x 105 cells per well) were seeded in a 6-well plate at a 
volume of 2 mL of RPMI-1640 growth medium with 10% FBS 30 minutes prior to 
transfection. For each transfection, 2.5 μg of DNA was added into 500 μL of 
RPMI medium without serum. 2.5 μL of PLUS™ reagent (at a 1:1 ratio to DNA) 
was then added directly to the diluted DNA. After gentle mixing and a 10 minute 
incubation at room temperature, 10 μL of Lipofectamine™ LTX was added into 
the diluted DNA solution, mixed gently and incubated for 35 minutes at room 
temperature to form DNA-Lipofectamine™ LTX complexes. The DNA-
Lipofectamine™ LTX complexes were added dropwise to each well containing 
cells and mixed gently by manually rocking the plate back and forth. 24 hours 
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after transfection, the cells were pelleted by centrifugation at 400xg and 
resuspended in RPMI-1640 culture medium with 10% FBS, gentamicin (50 
g/mL) and the selection antibiotic, G418 sulfate (500 g/mL). Every 2-3 days, 
the cells were pelleted and resuspended in fresh medium with 10% FBS, 
gentamicin (50 μg/mL), and G418 sulfate (500 μg/mL). Assays were performed 
2-6 weeks after the start of selection. 
 
Transient transfection of HeLa cells—On the day prior to transfection, 
HeLa cells were trypsinized and counted. Approximately 2 x 104 cells were 
seeded into each well of a 24-well plate in 0.5 mL of DMEM. Cell density was 
~30-50% confluent on the day of transfection. For each transfection, 250ng of 
DNA was diluted into 100 μl of DMEM without serum. 1 μl of Lipofectamine™ 
LTX was added into the diluted DNA solution, mixed gently and incubated for 30-
45 minutes at room temperature to form DNA-Lipofectamine™ LTX complexes. 
The DNA-Lipofectamine™ LTX complexes were added dropwise to each well 
containing cells and mixed gently by manually rocking the plate back and forth for 
a few seconds. After 4 hours of incubation with the DNA-Lipofectamine LTX 
complexes, the medium was aspirated out of each well and fresh DMEM with 
10% FBS, gentamicin (50 g/mL), penicillin (60 μg/mL) and streptomycin (100 
g/mL) was added to each well of cells. Cells were incubated at 37°C in a CO2 
incubator for 24 or 48 hours post-transfection before assaying. 
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Preparation of cells for FACS and quantitation of PPIX—While K562 cells 
were suspended in phenol red-free medium, HeLa cells were washed, scraped 
and resuspended in phosphate-buffered saline (PBS; 80 mM disodium hydrogen 
orthophosphate, 20 mM sodium dihydrogen orthophosphate, 100 mM sodium 
chloride, pH 7.5) before pipetting into BD Falcon tubes with cell strainer caps. 
Preparation of either K562 or HeLa cells for FACS was done under very low light 
conditions (1-2 Lux as measured by a Pyle PLMT68 light meter) in order to 
minimize phototoxicity caused by PPIX accumulation. FACS analyses were 
performed using a BD LSR II Analyzer (Becton, Dickinson, and Company) and 
FACSDiva Version 6.1.3 software. ZsGreen1 emission was measured between 
515 nm and 545 nm (530/30BP filter) when cells were excited using the 488 nm 
laser. In order to eliminate any background red fluorescence, the 633 nm-red 
laser was blocked during the collection of the PPIX emission data. PPIX emission 
was determined in the 619 nm and 641 nm range (630/22BP filter) when cells 
were excited with the 405 nm laser. Forward-scatter (FSC) versus side-scatter 
(SSC) dot plots were used to gate the whole cells and thus remove the 
contribution of the cell debris from the population being examined. A minimum of 
10,000 of the gated whole cells were then depicted in dot plots of SSC versus 
ZsGreen1 fluorescence, and the “green-fluorescent population” gate was defined 
based on untransfected HeLa cells as negative controls. Dot plots of SSC versus 
PPIX fluorescence were used to define the PPIX-accumulating cells for both the 
“green-fluorescent” and the “non-green fluorescent” populations. The PPIX gating 
was based on the negative control for PPIX, the pIRES2-ZsGreen1 vector-
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expressing cells. PPIX fluorescence values were normalized for transfection 
efficiency using the corresponding ZsGreen1 fluorescence value. Normalized 
fluorescence values were obtained by first dividing the mean PPIX fluorescence by the 
mean ZsGreen1 fluorescence for each cell population and secondly dividing by the 
mean PPIX fluorescence/ZsGreen1 fluorescence ratio of the pIRES2-ZsGreen1-
transfected cells. 
 
Light exposure assays—HeLa cells in 24-well plates were transfected 48 
hours prior to FACS analysis. Cells were washed twice with PBS and placed on 
ice (to prevent overheating) underneath a Sylvania incandescent flood lamp 
(150W, 120V) for 10 minutes. Light intensity at the samples was measured 
before each light exposure experiment using a Pyle PLMT68 light meter, and it 
was between 21-22 kLux for all experiments. The samples were resuspended 
and pipetted into tubes with cell strainer caps and analyzed first for ZsGreen1 
and PPIX fluorescence (as described above), and then for cell viability.  In order 
to determine the statistical significance of cell death directly attributable to 
mALAS2-induced PPIX accumulation and phototoxicity, samples were compared 
to the ZsGreen1 controls during one-way ANOVA evaluations.   
 
Cell viability assays—Cell death was assessed by measuring 
incorporation of either propidium iodide or DAPI into nuclear DNA, as these 
fluorescent dyes cross the plasma membrane in dying cells much more efficiently 
than in live cells. HeLa cell cultures were independently incubated with the 
fluorescent DNA-binding dyes propidium iodide (10 μg/mL) and DAPI (10 μg/mL) 
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for 5 min at 22oC. The cells were then analyzed by determining the fluorescence 
intensities using FACS. Fluorescence emission of nucleic acid-bound propidium 
iodide was measured between 585 nm and 625 nm (605/40BP filter) upon 
excitation of the cells using the 488 nm laser, while DNA-bound DAPI emission 
was measured between 440 nm and 460 nm (450/20BP filter) following excitation 
of the cells at 375 nm. Dot plots of SSC versus propidium iodide or DAPI 
fluorescence were used to define the respective gates, which were based on the 
control samples in which no propidium iodide or DAPI were added.  Cell viability 
was independently determined using the MTT dye reduction assay as described 
elsewhere (42,43). HeLa cells (5 x 103 cells per well) were seeded in 96-well 
plates, and on the following day were transfected with plasmids encoding 
mALAS2 variants as described above. Twenty-four hours after plasmid 
transfection, or 4 hours after addition of 100 M ALA, cells were exposed to light 
for 10 minutes. The culture medium was pipetted out, 50 μL of 2 mg/mL MTT 
was added to each well, and cells were incubated for an additional 4 hours at 
37 C. Upon solubilization of the cells with DMSO (100 μL/well) during a 10 
minute incubation, the solubilized, MTT-treated cells were thoroughly mixed by 
pipetting several times, and absorbance was measured at 540 nm using a 
μQuant plate reader (Bio-Tek Instruments, Inc.). For control and ALA-treated 
cells, cell death was calculated by dividing the number of DAPI-stained cells by 
the total number of cells. For ZsGreen1-, WT-, HPVT-, and R433K-expressing 
cells, cell death was calculated from the ZsGreen1-positive cell populations by 
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dividing the number of DAPI-stained cells by the total number of ZsGreen1-
positive cells. 
 
Confocal fluorescence microscopy—HeLa cells were grown in 
Thermoscientific™ Nunc™ Labtek™ sterile 4-well chambered coverglass until 
50% confluent, and then transfected as described above. Six hours later, the 
culture medium was supplemented with glycine to yield a final concentration of 
100 mM, and immediately before obtaining confocal fluorescence microscopy 
images of the cells, the medium was removed from the wells and the cells were 
washed with PBS three times. Live cell imaging was performed using a 3i-
Olympus spinning disk confocal microscope operated by Slidebook 5 software 
and equipped with a Photometrics Evolve EMCCD camera. The filter block used 
consisted of a 350/50 nm excitation filter, a BS400 beamsplitter, and a 630/75 
nm emission filter.  
 
Results 
Transient expression of mALAS2 variants causes accumulation of PPIX in 
HeLa cells—HeLa cells were transfected with mALAS2-encoding plasmids with 
or without mutations in the mALAS2 presequence and/or mature enzyme 
sequence (Table 2.1, Figure 2.1). Where indicated, the mALAS2 presequence 
was mutated at three cysteine residues, C11, C38, and C70, in order to yield 
nonfunctional HRMs and thus eliminate heme feedback inhibition of 
mitochondrial import (18,40). The plasmids were designed such that a single 
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bicistronic mRNA, encoding both mALAS2 and the fluorescent protein ZsGreen1, 
separated by an internal ribosomal entry site (IRES), would be produced. 
Transcriptional expression of mALAS2 and ZsGreen1 was under control of the 
constitutively active cytomegalovirus (CMV) promoter (44). Twenty-four hours 
post-transfection, wild-type mALAS2 with a wild-type presequence (WT ) 
expression caused a slight, but statistically significant as defined by Student’s t-
test (p<0.05), increase in PPIX accumulation (Figure 2.2A). The K313A mutation 
in ALAS2 leads to undetectable enzymatic activity values in vitro (45), and under 
ex vivo conditions this also appears to be the case, as no PPIX accumulated in 
K313A-expressing cells (K313A ), a result similar to that of the mammalian cells 
harboring the pIRES2-ZsGreen1 vector (ZsGreen1) alone (Figure 2.2A).  In  
 
 
Table 2.1. Plasmid constructs used to express murine ALAS2 variants in 
mammalian cell lines. 
 
Plasmid Name Mutations in 
mALAS2 Presequence Mature mALAS2 Sequence 
pIRES2-ZsGreen1 N/A1 N/A1 
pEF21 ---2 ---2 
pEF22 ---2 V423L,Y428R,P432E, 
R433I, G434N, E435Q and 
L437K 
pEF23 ---2 K313A 
pEF24 C11S, C38S and C70S ---2 
pEF25 C11S, C38S and C70S V423L,Y428R,P432E, 
R433I, G434N, E435Q and 
L437K 
pEF26 C11S, C38S and C70S K313A 
pEF31 C11S, C38S and C70S R433K 
1N/A, non-applicable; 2---, no mutations. 
69 
 
comparison to WT , the heptavariant mutations in the active site loop alone 
(HPVT ) and mutations in the presequence alone (WT) caused a statistically 
significant (p<0.05) increase in PPIX production in expressing cells (Figure 2.2A). 
The combination of the heptavariant mutations in the active site loop and 
mutations in the presequence (HPVT) resulted in variable PPIX production that 
was not statistically significant. Somewhat unexpectedly, it was expression of the 
mALAS2 variant with a mutated presequence containing the R433K mutation 
(R433K) that caused the largest accumulation of PPIX. Mutation of R433 residue 
to a lysine in the purified, mature enzyme results in an increase in activity to 
twice that of the wild-type enzyme (i.e., a 2-fold increase in the kcat value and a 
 
 
 
Figure 2.1. Murine ALAS2 protein schematic indicating mutated amino acid 
residues. The green dotted lines represent the relative locations of the three cysteines 
in the HRMs of ALAS2. C11 and C38 are in the ALAS2 presequence. K313A, R433K, 
and the heptavariant mutations and their respective positions are indicated according to 
the amino acid numbering previously described for mature mALAS2 (31,35,36). The 
amino acid positions according to the numbering for the precursor enzyme are written 
above the diagram. 
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1.65 to 1.85-fold enhancement in the specificity constants for glycine and 
succinyl-CoA over those of wild type, mature mALAS2)  (31). Similarly, the 
increase in PPIX accumulation in HeLa cells expressing the R433K precursor 
with a mutated presequence was approximately 2.5-fold compared to the cells 
expressing WT  and 2-fold in comparison to cells expressing WT (Figure 2.2A). 
 Because PPIX can be used as a photosensitizing agent for PDT of 
cancers, we examined the effect of combining mALAS2-induced PPIX 
accumulation with the chemotherapeutic drug paclitaxel, a well-characterized 
inhibitor of mitosis (46-48). Only mALAS2 variants with mutated presequences 
were used in the drug combination experiments, since those variants presented 
the most potential for PPIX accumulation, and thus, subsequent cell death 
resulting from light-induced phototoxicity. A dose response curve revealed that 
the concentration of paclitaxel that killed 25% of HeLa cells in 48 hours (IC25) 
was 10 nM (data not shown), and this concentration was chosen as the desired 
concentration for the PDT combination experiments. Paclitaxel had no 
statistically significant effect, as defined by Student’s t-tests, on the amount of 
accumulated PPIX in the mammalian cells transfected with any of the ALAS2 
variants after 48 hours (Figure 2.2B). The largest increase in PPIX fluorescence 
was observed with the R433K variant, regardless of whether or not paclitaxel was 
included in the culture medium (Figure 2.2B). 
 
Supplementation of cell culture medium with glycine leads to increased 
PPIX accumulation in mALAS2-expressing HeLa cells—Given that PPIX is a 
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Figure 2.2. Porphyrin accumulation in transiently transfected HeLa cells with 
mALAS2 WT- and variant-encoding plasmids. (A) HeLa cells transfected with 
mALAS2 variants with and without ( ) mutated presequences analyzed 24 hours after 
transfection. (B) HeLa cells transfected with mALAS2 variants with mutated 
presequences, in cells cultured in the absence or presence of 10 nM paclitaxel (Pct), 
analyzed 48 hours after transfection. Normalized PPIX fluorescence values were 
obtained by first dividing the mean PPIX fluorescence by the mean ZsGreen1 
fluorescence for each cell population and secondly dividing by the mean PPIX 
fluorescence/ZsGreen1 fluorescence ratio of the pIRES2-ZsGreen1-transfected cells. 
Each data set represents three separate experiments ± standard deviation (*p<0.05 and 
**p<0.01, Student’s t-test) [a.u., arbitrary units]. 
 
 
photosensitizer (49) and the Michaelis-Menten constant (Km) of mALAS2 for 
glycine, at 25±4 mM (3,25,34), is significantly higher than its intracellular 
concentration of approximately 2.5 mM (50), it is plausible that supplementation 
of the cell culture medium with glycine would lead to enhanced synthesis of ALA, 
and consequently, PPIX, which in turn might increase the efficacy of PPIX-
induced phototoxicity. To examine whether increased glycine concentration 
caused enhanced PPIX accumulation, HeLa cells transfected with mALAS2 (wild 
72 
 
type and variants) were grown in medium with different glycine concentrations 
(Figure 2.3A). Samples with culture medium supplemented with 100 μM ALA for 
4 hours served as a control for PPIX accumulation independent of glycine 
concentration (Figure 2.3B). The concentration and treatment times for ALA were 
chosen based on experiments indicating that the extent of PPIX accumulated in 
HeLa cells supplemented with 100 μM ALA was similar to that of HeLa cells 
expressing R433K, the mALAS2 variant that induces the highest levels of PPIX 
accumulation in these cells. HeLa cells expressing WT, HPVT or R433K in 
culture medium supplemented for 18 hours with 10 mM or 100 mM glycine 
exhibited significant increases in PPIX in comparison to the “no glycine” controls, 
with R433K again demonstrating the highest PPIX accumulation (p<0.01) (Figure 
2.4A). Supplementing the culture medium with either 10 mM or 100 mM glycine 
for cells expressing WT resulted in approximately 4- and 6-fold increases in PPIX 
accumulation, respectively, as compared to no glycine supplementation. For cells 
expressing R433K, glycine supplementation more than tripled the PPIX 
accumulation, representing a fourteen-fold increase over the control HeLa cells 
supplemented with glycine. Cells expressing HPVT were also affected by 
addition of either 10 mM or 100 mM glycine, increasing the PPIX by 1.4-fold and 
2.5-fold, respectively. Glycine elicited no effect on PPIX production in HeLa cells 
alone, those treated with 100 μM ALA, or HeLa cells expressing the pIRES2-
ZsGreen1 vector (Figure 2.3B).  
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Figure 2.3. Glycine supplementation of culture medium increases PPIX 
accumulation in HeLa cells expressing murine wild-type, HPVT, and R433K 
ALAS2.  (A) PPIX fluorescence 24 hours after transfection and 18 hours after 
supplementing culture medium with 10 mM glycine or 100 mM glycine. Normalized PPIX 
fluorescence values were obtained by dividing the mean PPIX fluorescence by the mean 
ZsGreen1 fluorescence for each cell population. Mean PPIX fluorescence values are 
representative of three separate experiments ± standard deviation (**p<0.01, one-way 
ANOVA) [a.u., arbitrary units].  (B) ZsGreen1 fluorescence versus PPIX fluorescence in 
HeLa cell populations supplemented with 100 mM glycine as measured by flow 
cytometry. In each dot plot, cells in the green-fluorescent range are represented in green 
and to the right of the vertical black line, while cells that are not green-fluorescent are in 
blue. Cells that are red-fluorescent due to PPIX accumulation are above the horizontal 
black line, while cells that are not red-fluorescent are below the horizontal black line. The 
percentage of cells in each quadrant is written in the corners of each dot plot. “Control” 
refers to non-transfected HeLa cells. 
 
Glycine and deferoxamine increase PPIX accumulation in mALAS2-
expressing K562 cells—We generated stable K562 human myelogenous 
erythroleukemia cell lines expressing mALAS2, expecting that these cells might 
accumulate high amounts of PPIX, due to their similarity to undifferentiated 
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erythrocytes (51). We expressed only WT and HPVT in order to test if HPVT 
could have higher activity in a cell line in which ALAS2 in normally expressed. 
Initially, the stable cell lines expressing WT did not show an increase in PPIX 
fluorescence as compared to regular K562 cells (Figure 2.4A), and we postulated 
that glycine availability was again a limiting factor, as we had observed in HeLa 
cells (Figure 2.3).  Another possible limitation upon PPIX accumulation could be 
a more effective conversion of PPIX into heme in K562 cells, in which case the 
inclusion of an iron-specific chelator such as deferoxamine should increase the 
PPIX fluorescence by reducing or even preventing this conversion. To address 
why the expression of mALAS2 alone did not cause a larger increase in PPIX 
and what could limit the ALAS2-induced PPIX accumulation, the culture medium 
supplemented with glycine to yield final concentrations of 10 mM or 100 mM 
glycine (Figure 2.4A and 2.4C) or deferoxamine mesylate to yield a final 
concentration of 100 M deferoxamine mesylate (Figure 2.4B and 2.4D). 
Expression of WT in K562 cells did not increase the cellular PPIX fluorescence, 
but PPIX fluorescence increased by more than 5– and 10–fold when the culture 
medium contained 10 mM glycine and 100 mM glycine, respectively (Figure 
2.4A). No significant differences were seen in cells not expressing mALAS2 
(Figure 2.4C) or in cells expressing HPVT when treated with 10 mM glycine 
(Figure 2.4A). However, in contrast to HeLa cells, when 100 mM glycine was 
used, cells expressing HPVT did exhibit an increase in PPIX fluorescence by 
approximately 3-fold (Figure 2.4A). 
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 Deferoxamine is a well-characterized iron-specific bacterial siderophore 
with a long history of clinical use in iron chelation therapy. Deferoxamine has the  
 
 
Figure 2.4. Stable expression of murine ALAS2 variants in K562 cells results in 
PPIX accumulation when culture medium is supplemented with either glycine or 
deferoxamine. (A) PPIX fluorescence after supplementation of the culture medium with 
glycine. (B) PPIX fluorescence after supplementation of the culture medium with 
deferoxamine (+D). (C) PPIX fluorescence of K562 cell populations supplemented with 
glycine. The blue area represents cells that do not express ZsGreen1, and the green 
area represents the population that expresses ZsGreen1. K562 cells that express 
ZsGreen1 are not affected by glycine supplementation of the culture medium (upper 
plots), while cells that express WT exhibit a significant increase in PPIX fluorescence 
when the culture medium is supplemented with glycine (lower plots). (D) PPIX 
fluorescence of K562 cell populations grown in culture media containing deferoxamine. 
Cell growth in the presence of deferoxamine significantly increases the PPIX 
fluorescence in K562 cells expressing WT, but does not affect PPIX fluorescence in cells 
expressing only ZsGreen1 or HPVT, as indicated by the number of cells within the red 
dotted-line boxes. 
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potential to increase PPIX by decreasing the cellular iron concentration, thereby 
inhibiting the conversion of PPIX to heme (52,53). Treatment of K562 cells with 
deferoxamine for 18 hours caused no change in PPIX fluorescence in cells not 
expressing mALAS2 or cells expressing HPVT. Deferoxamine did cause a 
significant increase in PPIX in cells expressing WT, in which case the mean PPIX 
fluorescence increased from 1.4-fold over cells expressing ZsGreen1, to 2.4-fold 
with deferoxamine (Figure 2.4B and 2.4D). 
 
 
PPIX primarily accumulates and localizes at the plasma membrane in 
HeLa cells expressing R433K—To evaluate cellular intactness and accumulated 
PPIX distribution in the transfected HeLa cells, we used confocal microscopy to 
visualize the fluorescent PPIX in individual HeLa cells (Figure 2.5A) and HeLa 
cells transfected with either the pIRES2-ZsGreen1 vector (Figure 2.5B) or pEF31 
(harboring R433K) (Figure 2.5C). Transfected cells were grown in medium 
supplemented with 100 mM glycine for 18 hours in preparation for imaging. The 
outline of intact cells, and thus their morphological integrity, was evident in the 
three cases. As expected, green fluorescence was visualized in the transfected 
(Figures 2.5B and 2.5C) but not control HeLa cells (Figure 2.5A). In fact, green 
fluorescence, arising from the soluble ZsGreen1 green fluorescent protein was 
observed evenly distributed throughout the cytoplasm of the HeLa cells 
transfected with either pIRES2-ZsGreen1 (Figure 2.5B) or the R433K-expression 
plasmid (Figure 2.5C). While the enzyme protoporphyrinogen oxidase catalyzes 
PPIX production exclusively within the mitochondrion, PPIX accumulated 
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primarily within the plasma membranes of HeLa cells expressing R433K, as 
visualized by the characteristic red fluorescence; however, PPIX build-up was 
also apparent within the cells (Figure 2.5C). Thus, it appears that much of the  
 
Figure 2.5.  Fluorescence microscopy of HeLa cells expressing GFP and the 
R433K mALAS2 variant. From left to right for each row, the panels correspond to (1) 
brightfield, (2) green fluorescence, (3) red fluorescence, (4) superimposed green and (5) 
red fluorescence, and superimposed brightfield, green fluorescence, and red 
fluorescence images. (A) HeLa cells grown to 100% confluency in culture medium with 
100 mM glycine. (B) HeLa cells transfected with pIRES2-ZsGreen1 and grown in culture 
medium to 100% confluency with 100 mM glycine. (C) HeLa cells transfected with 
pEF31, which expresses the R433K variant from the CMV promoter in the pIRES2-
ZsGreen1 vector (Table 2.1), and grown to 100% confluency in culture medium with 100 
mM glycine. (D) HeLa cells transfected with pEF31 and grown in culture medium to 80% 
confluency with 100 mM glycine. Pictures were obtained 24 hours after transfection and 
18 hours after glycine supplementation. ZsGreen1 (green) is present throughout the cell, 
while PPIX (red) accumulates at the plasma membrane of cells expressing R433K and 
surrounding cells.  
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PPIX produced in the mitochondria eventually accumulates in the plasma 
membrane, entirely consistent with the fact that PPIX is a relatively lipophilic 
molecule. Of note, PPIX accumulated in not only transfected cells, but also in 
surrounding cells, indicating that PPIX could leave the transfected cells and be 
taken up by nearby cells (Figure 2.5C). It is very likely that, additionally, PPIX 
accumulated in organelle membranes within the cell, such as in the 
mitochondrion, but since PPIX photobleached within a few seconds under the 
conditions utilized here, it was not possible to obtain high-resolution organelle 
images with our current microscopic parameters. 
 
ALAS2-induced PPIX accumulation followed by light exposure combined 
with paclitaxel treatment causes cell death—Both propidium iodide and DAPI 
staining were utilized to assess cell viability after mALAS2-induced PPIX 
accumulation, light exposure, and paclitaxel treatment, based on the specific 
fluorescence emission of each dye when bound to the DNA of intact cells.  Stains 
were added to cell samples 48 hours after transfection, and the fluorescence of 
DNA-bound propidium iodide and DAPI were measured by flow cytometric 
analysis using the respective fluorescence emission maxima of 613 nm and 460 
nm. Expression of WT or HPVT did not significantly increase cell death following 
light exposure. However, expression of R433K caused a statistically significant 
(p<0.05) increase in cell death of up to 30%, as measured both by propidium 
iodine (Figure 2.6A) and DAPI (Figure 2.6B) staining, in comparison to 
expression of ZsGreen1 alone. Addition of paclitaxel increased cell death in all 
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samples, including controls, by 10-25%. HeLa cells expressing R433K and 
treated with paclitaxel exhibited the highest percentage of up to 50% cell death 
(Figure 2.6A-B). Combination of paclitaxel with mALAS2-induced PPIX 
accumulation and light treatments exhibited an additive effect in causing death in 
HeLa cells.  
 
 
Figure 2.6. Light-induced cell death of HeLa cells expressing mALAS2 variants. (A) 
Cell death measured by changes in DNA-bound propidium iodide fluorescence. (B) Cell 
death measured by changes in DNA-bound DAPI fluorescence. HeLa cells were 
transfected with expression plasmids for either wild type (WT) or mALAS2 variants and 
treated with 10 nM paclitaxel 4-hour post-transfection.  48 hours after transfection, cells 
were stained and analyzed by flow cytometry. Cell death percentage values were 
compared to that of the pIRES2-ZsGreen1-transfected cells control. Each data set 
represents three separate experiments ± standard deviation (*p<0.05 and **p<0.01, 
Student’s t-test). 
 
 
Supplementation of cell culture medium with glycine enhances 
phototoxicity and cell death in mALAS2-expressing HeLa cells—The 
phototoxicity and subsequent cell death caused by mALAS2-induced PPIX 
accumulation, when the culture medium was supplemented with glycine, were 
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also investigated in HeLa cells. Cell viability was measured using propidium 
iodide (data not shown), DAPI staining, and MTT assays (Figure 2.7) 24 hours 
post-transfection, 18 hours after glycine addition, and 4 hours after ALA addition. 
Significant cell death was ascribed to those samples that exhibited more cell 
death compared to the pIRES2-ZsGreen1-transfected cells with the same glycine 
concentration as determined by one-way ANOVA (p<0.05). Transfection of HeLa 
cells with the pIRES2-ZsGreen1 plasmid caused a decrease in cell viability by an 
average of 30%, which can be attributed to the mild cytotoxicity of the 
transfection reagents (54).  
Expressing WT, regardless of the glycine concentration in the culture 
medium, caused approximately 70% cell death following light exposure, as 
measured by DAPI staining (Figure 2.7A-B). In the MTT assays, expression of 
WT only caused statistically significant cell death (p<0.05) with supplementation 
of 100 mM glycine, in which case only an average of 15% of cells remained 
viable (Figure 2.7C). HeLa cells expressing HPVT or R433K did exhibit a glycine-
dependent increase in cell death when the glycine concentration reached 100 
mM as measured by both DAPI staining and MTT assays. When 100mM glycine 
was added, cells expressing HPVT decreased from an average of 81% viable to 
13% viable, and cells expressing R433K decreased from 58% viable to 25% 
viable as measured by MTT assays (Figure 2.7C). ALA treatment did not cause 
significant cell death (p>0.05), regardless of glycine concentration, when 
measured by either DAPI staining or MTT assays. 
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Figure 2.7. Light-induced cell death in murine ALAS2 variants-expressing HeLa 
cells cultured in a medium supplemented with glycine. (A) Cell death, as assessed 
by DAPI fluorescence, are representative of three separate experiments ± standard 
deviation (*p<0.05 and **p<0.01, one-way ANOVA). (B) Cell death in HeLa cell 
populations grown in culture medium supplemented with glycine. The percentage of cells 
in each quadrant is written in the corners of each dot plot. (C) Cell viability as measured 
by metabolism of MTT. Cells were transfected 24 hours before light treatment, and 100 
mM glycine was added 18 hours before light treatment. Cell viability percentage values 
are normalized to MTT metabolism in healthy, untreated HeLa cells and are 
representative of at least three separate experiments ± standard deviation (*p<0.05, 
one-way ANOVA). “Control” refers to non-transfected HeLa cells. 
 
 
Discussion 
 Photodynamic therapy (PDT) is a widely utilized clinical procedure for 
many types of cancer, as well as dermatological conditions such as psoriasis 
and schleroderma (55-57). PDT is often initiated by application of the pro-drug 5-
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aminolevulinic acid (ALA) to the patient in order to photosensitize the tissue to 
be treated (49). ALA-PDT is very effective, has minimal side effects and is being 
tested in numerous clinical trials on a wide-spectrum of cancers (49). There are, 
however, some limitations to ALA-PDT and other PDTs that provide 
opportunities for improvement. For example, there is no specific mechanism that 
targets PPIX to tumor cells after ALA has been applied, other than a slightly 
preferential uptake of photosensitizers by hyperproliferating cells (58). 
Consequently, normal tissue can be damaged from the procedure due to 
unintentional exposure to light resulting in pain, and conversely, not all 
hyperproliferating cells necessarily become highly sensitized (55,59) . In an 
attempt to restrict photosensitivity by biological, rather than just chemical or 
physical means, an adenovirus expressing human ALAS2 with mutated HRMs 
was generated and H1299 lung carcinoma cells were successfully infected (40). 
The adenovirus-infected H1299 cells accumulated more PPIX and became more 
photosensitive than cells supplied with ALA in their media, indicating that 
delivery of ALAS to tumors could potentially be a useful tool for PDT not only for 
better targeting, but also for greater photosensitivity (40). However, the cell 
death was only 26% even in the presence of deferoxamine (40), leading us to 
postulate that one or more highly active variants of mALAS2 (31,35) would 
increase PPIX accumulation, phototoxicity, and targeted cell death sufficiently to 
make the approach more clinically attractive.   
To explore the ability of mALAS2 variants to cause accumulation of PPIX 
in mammalian cells, we transfected cells, of both erythroid and non-erythroid 
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lineages, with murine ALAS2-expressing plasmids, and quantified the PPIX 
fluorescence using FACS analysis. In HeLa cells, we transfected plasmids 
encoding mALAS2 both with and without mutated presequences and with or 
without mutations in the mature enzyme sequence (Table 2.1, Figure 2.1).  As 
with many mitochondrial proteins, ALAS2 is synthesized in the cytosol and 
contains a sequence at its N-terminus that targets ALAS2 for mitochondrial 
import after its synthesis (18). Within the N-terminus of the ALAS2 precursor, 
there are three HRMs as recognized by adjacent cysteine-proline residues that 
have the potential to bind heme. The HRMs located within the presequence of 
ALAS2 (C11 and C38) have been shown to bind heme (24) and subsequently 
inhibit the mitochondrial import of ALAS2 (18). Our experiments support the 
existing data that the cysteines in the HRMs bind heme, and that mutation of 
these HRMs relieve the inhibition of mitochondrial import, thus resulting in 
increased mature, functional ALAS2, as reflected by increased cellular 
concentrations of PPIX when the HRMs are mutated (Figure 2.2A). In our study, 
when the HRMs in the presequences of the mALAS2 constructs were mutated to 
relieve heme inhibition on mitochondrial import, there were significant increases 
in PPIX accumulation in HeLa cells expressing WT, HPVT, and R433K (Figure 
2.2A-B).  
 We tested several mALAS2 variants, covering a range of in vitro activity 
from undetectable to higher than wild-type, for capacity to stimulate PPIX 
accumulation (31,35,36,60). Transfection of HeLa cells with the negative control 
plasmid harboring K313A  resulted in no PPIX increase, as expected (Figure 
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2.2A). The mutation of K313 leads to undetectable enzymatic activity in vitro, 
attributable to the role of K313 in formation of a Schiff-base linkage with the PLP 
cofactor (36), and its additional function as a general base catalyst during the 
ALAS-catalyzed reaction (3,28,36,61). In preliminary studies with HeLa cells, it 
was observed that expression of HPVT , which has seven mutations in its active 
site loop, yielded significantly more accumulated PPIX than expression of the 
pIRES2-ZsGreen1 vector control plasmid. HPVT  was chosen for this study as 
the seven mutations of non-conserved residues in the active site loop resulted in 
the most active recombinant protein isolated from a variant library at 20°C (35). 
Lendrihas et al. (35) hypothesized that these mutations in the active site loop, 
which increase both hydrophilicity and basicity, destabilize the loop by both 
increasing solubility and eliminating hydrophobic and electrostatic interactions 
that would typically act to stabilize the loop in its closed confirmation. However, 
the hyperactivity of HPVT  was temperature-dependent; while at a temperature 
of 20 C these seven mutations increased the kcat value of the recombinant, 
mature enzyme to more than 10 times of that of the WT enzyme, at 35 C the kcat 
values were nearly the same (35). While the levels of accumulated PPIX in HeLa 
cells expressing HPVT were significantly affected by supplementation with 
glycine (p<0.01), those in K562 cells expressing HPVT were only modestly 
increased when the medium was supplemented with 100 mM glycine. However, 
the HPVT-promoted PPIX concentration enrichments were much lower than 
those in cells expressing WT or R433K (Figures 2.3 and 2.4). The relatively low 
levels of PPIX associated with HPVT expression are presumably due to the 
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temperature-dependent activity profile of this particular mALAS2 variant. HPVT 
was isolated from a library of mALAS2 variants engineered to possess greater 
enzymatic activity than wild type mALAS2 by targeting the active site loop to 
acquire different degrees of mobility (35). Since the mutations in HPVT 
destabilized the active site loop and altered the protein conformation (35), it 
would not be surprising if this variant had a decreased cellular stability. 
Additionally, the HPVT mutations may affect protein-protein interactions, 
specifically the ability of mALAS2 to interact with a known binding partner, 
succinyl-CoA synthetase (62).  
The simple addition of the non-toxic substrate glycine to the cell media 
increased PPIX production by WT, HPVT, and R433K significantly. When the 
culture medium was supplemented to a final concentration of 10 mM or 100 mM 
glycine, PPIX production in HeLa cells expressing WT was increased by more 
than 4- and 6-fold for each concentration, respectively (Figure 2.3). In K562 cells 
expressing WT, the effect was even larger, as PPIX increased by more than 5- 
and 10-fold for 10 mM and 100 mM glycine, respectively (Figure 2.4A and 2.4C). 
The slightly higher increases in PPIX concentrations in the K562 cells when 
treated with glycine could be due to the stable expression of ALAS2 versus the 
transient transfection used in the HeLa cells. However, the ability of the K562 
cells to tolerate higher expression of WT and production of PPIX, in comparison 
to HeLa cells, might also be attributable to their erythroid lineage. K562 cells are 
of the erythroleukemic cell type, and bear some proteomic resemblance to 
undifferentiated erythrocytes (51,63) and express endogenous ALAS2. Thus 
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while expressing ALAS2 in HeLa cells introduces an enzyme that does not 
normally exist in epithelial cells, K562 cells may adapt more easily to the 
expression and up-regulation of the heme biosynthetic pathway.  It seems likely 
that the capacity of mALAS2 to accumulate PPIX will be found to vary in other 
mammalian cell types as well. 
Supplementing the culture medium of K562 cells expressing WT with 100 
μM deferoxamine, an iron-chelator previously shown to increase the amount of 
PPIX in ALAS adenovirus-infected H1299 cells (40), resulted in increase in the 
mean PPIX fluorescence per cell (Figure 2.4B and 2.4D), but it was much less 
than with glycine supplementation. However, the modest increase was similar to 
what Gagnebin et al. (40) observed in the ALAS adenovirus-infected cells, 
suggesting the much larger increases reported here with R433K and glycine 
supplementation represent substantial advancements in our ability to 
overproduce PPIX in mammalian cells.  R433K is only twice as active as WT in 
vitro, and it is reasonable to believe that significantly more active variants could 
be readily produced via directed evolution, and that these variants would facilitate 
even greater levels of PPIX accumulation, perhaps to the point of expanding the 
clinical applicability of PPIX-based PDT.   
The HeLa cells that accumulated the highest amount of PPIX were those 
expressing R433K. The R433K mutation was analyzed in 1998 by Tan et al. (31) 
in a study that identified the nearby R439 as being a conserved residue in many 
α-family PLP-dependent enzymes, as well as being involved in binding of the 
amino acid substrate during catalysis (31). In that study, the kinetic parameters 
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were defined for R439L, R439K, R433L, and R433K. Although not the primary 
focus of the article, the kinetic parameters for R433L were found to be 
comparable to those of the wild-type at 37°C, while for R433K the kcat was 
increased by two-fold, with no effect on the Michaelis constants, resulting in a  
doubling of catalytic efficiency for both substrates (31). In the results detailed 
here, expression of R433K in HeLa cells produced a 2- to 3-fold increase in PPIX 
in comparison to WT, and a 4- to 6-fold increase in PPIX fluorescence in 
comparison to cells transfected with the pIRES2-ZsGreen1 vector control or 
HeLa cells alone (Figure 2.2). When the culture medium was supplemented with 
glycine, PPIX accumulation increased by 13- to 15-fold in comparison to cells 
transfected with the pIRES2-ZsGreen1 vector control or HeLa cells alone, and 
represented the conditions for the highest cellular PPIX accumulation. Given that 
within these samples there were cells fluorescing with PPIX that were not 
ZsGreen1-expressing (Figure 2.3B), some of the PPIX produced in the R433K- 
and WT-expressing HeLa cells appears to have been transported out of the cells 
into the culture medium, where it was then taken up by non-transfected cells. 
These populations of red-fluorescing cells were comparable to those cells in 
culture medium supplemented with ALA (Figure 2.3B). This is a very important 
finding in terms of the potential of these constructs for photodynamic therapy, as 
it indicates that the PPIX produced within a delivery cell could be transported into 
surrounding diseased tissue and accumulate to clinically relevant levels.   
The subcellular distribution of a photosensitizing agent might have 
important consequences in regards to PDT efficacy (64).  Fluorescence 
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microscopy was successfully utilized to visualize PPIX accumulation in R433K 
expressing HeLa cells.  Due to the extremely short time (a few seconds) it took 
for PPIX to photobleach, the resolution could not be optimized for visibility of 
individual organelles such as mitochondria and nuclei. However, it was possible 
to observe that PPIX had accumulated in the plasma membranes of the R433K 
expressing cells; and this fluorescence was not seen in the pIRES2-ZsGreen1 
vector-expressing cells (Figure 2.5). It also appears that PPIX can exit the 
transfected cells, potentially via ABC transporters such as ABCB6 (65,66) or 
ABCG2 (67,68), and enter surrounding cells. Presumably, the lipophilic PPIX 
accumulated in the organelle membranes as well, but direct microscopic 
confirmation of PPIX accrual in organelle membranes awaits approaches 
resulting in better resolution than we were able to achieve here.  
 In order to study the photosensitivity of cells that accumulated PPIX 
(caused by expression of WT, HPVT, and R433K), we performed light treatments 
using an incandescent lamp, which emits light in the visible and infrared spectral 
regions (400-1000 nm). The cells were exposed for 10 minutes before FACS 
analysis of PPIX and cell death. Expression of the ZsGreen1 protein alone 
caused a toxicity that was independent of light treatment, and thus significant cell 
death was measured against the pIRES2-ZsGreen1 vector-transfected cells 
(p<0.05) as opposed to HeLa cells alone (Figure 2.7). Regardless of glycine 
concentration, the expression of WT led to a significant increase in cell death by 
1.4- to 2-fold.  R433K and HPVT, when the culture medium was supplemented 
with 100 mM glycine, also caused significant increases in cell death by 2.1- and 
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1.6-fold, respectively.  With no or 10 mM glycine supplementation the error was 
too high for any of the increases to be significant, although there was a trend 
towards increased cell death. For WT and R433K, increased PPIX accumulation 
correlates with increased cell death after light treatment. In spite of the more 
modest increases in PPIX accumulation, light-induced death also occurred in 
HPVT-expressing cells. This finding led us to suggest that toxicity inherent to the 
overproduced HPVT protein is the other contributing factor to cell death. 
Although purified recombinant, mature HPVT is more active than WT at 37°C 
(with an enhancement of approximately 1.5 in the kcat value at 37°C vs. a 15.5-
fold increased kcat at 20 °C) (35), when expressed in mammalian cells, HPVT is 
not as active as WT, as determined by PPIX fluorescence. Since expression of 
HPVT paired with glycine supplementation caused significant cell death (Figure 
2.7), the potential role of another toxic heme pathway intermediate, such as the 
pro-oxidant ALA (69-72), in causing cell death, is plausible. However, at present, 
different levels of protein expression [Quantification of ALAS2 and variant protein 
levels was not feasible due to the unavailability of a functional ALAS2 antibody.] 
and distinct modulation of the enzymatic activity between ALAS2 and variants 
cannot be ruled out as possibilities. Treatment with 100 μM ALA, a positive 
control for PPIX accumulation, caused a similar cell death after light exposure to 
expression of the ZsGreen1 protein alone. In summary, the highest cell death 
was seen in light-treated HeLa cells expressing ZsGreen1 and either WT, HPVT, 
or R433K, in culture medium supplemented with 100 mM glycine. The total cell 
death was observed to be as high as 90% in the cells expressing both ZsGreen1 
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and R433K. This represents a substantial improvement upon the 26% cell death 
reported previously (40), and indicates that this approach, if carefully developed, 
may eventually find some clinical utility. 
Because ALAS2, especially highly stable and active variants of ALAS2, 
would be useful in the development of multiplex cancer treatments involving PDT, 
we experimented with combination PDT and drug treatments of HeLa cells. 
Paclitaxel (Taxol) is currently approved in the United States for the treatment of 
AIDS-related Kaposi sarcoma (73), breast cancer (74), non-small lung cell lung 
cancer (75), and ovarian cancer (76). Paclitaxel induces apoptosis in cancer cells 
by binding to tubulin and inhibiting the disassembly of microtubules, thereby 
resulting in the inhibition of cell division (46,77). As expected, paclitaxel did not 
affect PPIX accumulation, as indicated by the similar mean PPIX fluorescence 
values between untreated and paclitaxel-treated cells (Figure 2.2B).  However, 
paclitaxel had an additive effect to PDT and increased cell death in all samples 
by 10-25%. HeLa cells expressing R433K treated with paclitaxel exhibited the 
highest percentage of cell death (Figure 2.6A-B). Ever since PDT was first shown 
to be able to elicit an immune response (78), many recent advances in PDT are 
aiming toward creating PDT-generated cancer vaccines (79). Using highly active 
and stable ALAS2 variants as part of a vaccine strategy for photosensitization 
may be useful for this vaccine approach. Further experiments, both in cell culture 
and live animals, are necessary to test for potential immune response stimulated 
by ALAS2-PDT. 
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 In this study, we have shown that transfecting mammalian cells, of both 
erythroid and non-erythroid lineages, with mALAS2 variants, is an effective way 
to stimulate cellular PPIX accumulation. Furthermore, supplementing the culture 
medium with glycine vastly increases the intracellular PPIX levels when cells 
express either WT or R433K. These data offer new ways to accumulate high 
levels of the photosensitizer PPIX in cancer cells for more targetable and efficient 
PDT. Human ALAS2 variants with higher than normal activity are now known to 
occur in nature, and are associated with a form of erythropoietic protoporphyria 
known as X-linked dominant protoporphyria, which is characterized by a 24-fold 
increase in erythrocyte PPIX concentrations (39). It would be appropriate if these 
variants were eventually utilized in PDT, and could thereby allow clinicians to 
exploit one disease to treat or cure others. 
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CHAPTER 3: MUTATIONS IN THE C-TERMINUS OF HUMAN ERYTHROID  
5-AMINOLEVULINATE SYNTHASE ASSOCIATED WITH X-LINKED 
ERYTHROPOIETIC PROTOPORPHYRIA ALTER ENZYME STRUCTURE, 
KINETICS, AND EX VIVO ACTIVITY                                                         
 
 
Abstract 
Five different frameshift mutations in the final coding exon of the human 
erythroid ALAS (hALAS2) gene are associated with X-linked erythropoietic 
protoporphyria (XLEPP), a disease phenotypically characterized by elevated 
levels or protoporphyrin IX (PPIX) and zinc protoporphyrin in erythroblasts. This 
is apparently due to enhanced cellular ALAS2 activity, but the biochemical 
relationship between these C-terminal mutations and increased ALAS2 activity is 
not well understood. Mutations in the hALAS2 C-terminus associated with 
XLEPP were characterized using purified recombinant hALAS2 to compare 
kinetic and structural parameters and studied ex vivo in HeLa and K562 cells. 
Two XLEPP variants, delAGTG and Q548X, when compared to wild-type 
hALAS2, exhibited higher catalytic constants and affinity for succinyl-CoA, 
increased transition temperatures, and caused porphyrin accumulation in HeLa 
and K562 cells. Another XLEPP mutation, delAT, had an increased transition 
temperature and caused porphyrin accumulation in mammalian cells, but 
exhibited a reduced catalytic constant at 37°C in comparison to wild-type 
hALAS2. The XLEPP variants were more structurally responsive upon binding of 
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succinyl-CoA, and adopted distinct features in tertiary and PLP-cofactor binding 
site structure. These results imply that the C-terminus of hALAS2 is important for 
regulating its structural integrity, which affects kinetic activity and stability. 
 
 Introduction 
5-Aminolevulinate synthase (ALAS) is a homodimeric, pyridoxal-5’-
phosphate (PLP)-dependent enzyme that catalyzes the first and key regulatory 
step of heme biosynthesis in non-plant eukaryotes, as well as the α-subclass of 
purple bacteria (1-3). The reaction involves the condensation of glycine and 
succinyl-CoA to produce 5-aminolevulinate (ALA), CoA, and carbon dioxide (1). 
Animal genomes encode two highly conserved but differentially expressed ALAS 
genes, a housekeeping gene (ALAS1) and an erythroid-specific gene (ALAS2) 
(4). In humans, mutations in ALAS2 can result in two very different diseases, X-
linked sideroblastic anemia (XLSA) and X-linked erythropoietic protoporphyria 
(XLEPP).  
In XLSA, the mutation of ALAS2 leads to a decrease in activity, and thus a 
decrease in porphyrin synthesis, resulting in iron accumulation in the 
mitochondria of erythroblasts and anemia (5-8). ALAS2 mutations associated 
with XLSA have been identified in exons 4-11 of the ALAS2 gene, which encode 
the highly conserved catalytic core region of the enzyme (9). The discovery of 
XLSA began with reports that ALAS activity in the bone marrow of inherited 
sideroblastic anemia patients is decreased, indicating that impairment of heme 
biosynthesis may induce the onset of certain sideroblastic anemias (10-12). 
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Shortly after ALAS2 was mapped to region Xp11.21 of the X chromosome 
(13,14), the first sideroblastic anemia patient with a mutation in ALAS2 was 
reported  (15), supporting the theory that ALAS2 deficiency results in both a 
decreased supply of heme for hemoglobin and iron accumulation in the 
mitochondria of erythroblasts.  Since the identification of the first XLSA patient, at 
least 61 different mutations in ALAS2 in patients with XLSA have been identified 
(9,16-18). In more than 50% of XLSA patients, the mutation in ALAS2 decreases 
the affinity of ALAS2 for its cofactor PLP, and these patients are responsive to 
treatment with oral pyridoxine, which increases the amount of available PLP 
(9,17). In patients not responsive to pyridoxine, the ALAS2 mutations can create 
a premature stop codon or alter enzyme stability, leading to a decrease in protein 
level (9). ALAS2 protein levels can also be decreased as a result of mutations in 
the ALAS2 promoter, which decrease the transcription of ALAS2 resulting in 
XLSA (19). It is clear that a single amino acid change in a variety of locations in 
ALAS2 can decrease its function in vivo, and the mechanism by which the 
activity is reduced can be due to a decreased affinity for its PLP cofactor, affinity 
for its substrate/s, stability, and/or transcription.  
Yet, in 2008, C-terminal mutations in patients that lead to an increase in 
ALAS2 function were discovered (20), raising the question of how certain 
mutations in the C-terminus of ALAS2 cause decreased function, while other 
mutations in the same region result in an increased function. In XLEPP, ALAS2 
mutations in the C-terminal region lead to increased activity, and thus an 
accumulation of the heme precursor, protoporphyrin IX (PPIX), as well as zinc-
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protoporphyrin (20). In contrast to XLSA, all mutations known associated with 
XLEPP are located in the final exon, exon 11, which encodes the far C-terminus 
(20-22) (Table 3.1). The final 33 amino acids of ALAS2 are highly conserved and 
yet have diverged from the ALAS1 isoform, suggesting that these residues may 
have an erythroid-specific function (20). Additionally, the C-terminal amino acids 
are conserved in higher eukaryotes but not present in prokaryotes, and deleting 
the final 33 amino acids of recombinant hALAS2 results in an increase in the 
catalytic activity (21). Given that mutations at the C-terminus can result in either a 
decrease (9,16) or increase (20,22,23) in the function of hALAS2, the 
mechanisms by which the C-terminus of hALAS2 can determine its activity 
and/or stability are of particular interest. 
 
Here we characterize the kinetics, thermostability, and structure of the 
XLEPP variants by evaluating ex vivo activity in HeLa and K562 cells expressing 
hALAS2 and XLEPP variants, and using purified recombinant hALAS2 for kinetic 
analyses, acrylamide fluorescence quenching, and CD spectroscopy. We 
  
Table 3.1. C-terminal amino acid sequences resulting from XLEPP mutations. 
 
 Genetic 
mutation 
Protein 
name 
hALAS2 sequence 
    
 
 
Wild-type 
hALAS2 542
  AVGLPLQDVSVAACNFCRRPVHFELMSEWERSYFGNMGPQYVTTYA  
 
c.1699-1700 
DelAT 
(M567E) 542
  AVGLPLQDVSVAACNFCRRPVHFELE  
 
c.1706-1709 DelAGTG 542  AVGLPLQDVSVAACNFCRRPVHFELMSGNVPTSGTWGPSMSPPMPEKPAA 
 
 
c.1642C>T Q548X 542  AVGLPLQ 
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demonstrate that the C-terminus of hALAS2 is important not only for controlling 
its enzymatic activity, but also for maintaining structural integrity.  
 
Materials and Methods 
Reagents—Aprotinin, pepstatin, leupeptin, PMSF, ampicillin, β-
mercaptoethanol, pyridoxal 5’-phosphate, succinyl-CoA, thiamine pyrophosphate, 
and NAD+ were obtained from Sigma-Aldrich Chemical Company. Glucose, 
glycerol, acetic acid, methanol, glycine, disodium hydrogen orthophosphate, 
sodium dihydrogen orthophosphate, EDTA, MOPS, tryptone, yeast extract, 
sodium chloride, tricine, ammonium sulfate, and potassium hydroxide were 
purchased from Fisher Scientific. Centricon concentrators were from Millipore. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis reagents and Phusion 
DNA Polymerase were acquired from Thermo Scientific. 5-Aminolevulinic acid 
hydrochloride was purchased from Acros Organics. BmtI, SalI, BlpI, and BamHI 
restriction enzymes were obtained from New England BioLabs, Inc. 
Oligonucleotides were synthesized by Integrated DNA Technologies. T4 DNA 
ligase and ligase buffer were obtained from Thermo Scientific Fermentas and a 
bicinchoninic acid protein determination kit was purchased from Thermo 
Scientific Pierce.   
   
Plasmids for mammalian expression and protein purification—The following 
mutations: c. 1699-1700 AT deletion (delAT, which results in a frame-shift 
mutation leading to a truncated ALAS2 protein with a glutamate (E567) as the C-
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terminal amino acid (20) and c.1705-1708 AGTG deletion (delAGTG, which 
results in the E569G mutation and a 23 amino acid, non-related ALAS C-
terminus (20) were introduced into the cDNA of hALAS2 using the QuikChange 
method (Stratagene), and confirmed by DNA sequencing. The plasmids 
encoding the wild-type hALAS2, delAT, delAGTG, and Q548X sequences were 
pSD1, pSD2, pSD3, and pQ548X, respectively. The cDNAs for these proteins 
were under the control of the Escherichia coli alkaline phosphatase promoter 
(24). For expression plasmids used in the transfection of mammalian cells, the 
wild-type precursor hALAS2 cDNA (GenBank: X56352.1) was individually 
subcloned into the multiple cloning site of the pIRES2-ZsGreen1 vector 
(purchased from Clontech Laboratories, Inc. Mountain View, CA) using the BmtI 
and BamHI restriction sites. The digested hALAS2-encoding fragment was 
ligated into the digested pIRES2-ZsGreen1 vector using T4 DNA ligase in ligase 
buffer at 16°C. Electrocompetent BL21(DE3) cells were transformed by 
electroporation with the ligated plasmid DNA and selected by spreading the 
transformed cells on LB agar medium containing 10 µg/mL kanamycin sulfate. 
Plasmid DNA was purified from a single colony using a QiaPrep Spin Miniprep kit 
(Qiagen Inc.), and the sequence of the cloned DNA was verified by Genewiz, Inc. 
in New Brunswick, NJ. The resulting plasmid was named pEF27. For the 
mammalian expression plasmids encoding the precursor XLEPP variants, the 
cDNAs encoding the mutated hALAS2 C-termini were retrieved from pSD2 and 
pSD3 and subcloned into pEF27 using the BlpI and BamHI restriction sites. The 
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resulting plasmids were named pEF28 and pEF29, encoding delAT and 
delAGTG, respectively. 
In order to purify hALAS2 and the XLEPP variant proteins using nickel affinity 
chromatography, we added six histidine codons to the cDNA sequence encoding 
the mature hALAS2 N-terminus. The mature wild-type hALAS2 was amplified 
from pSD1 using the oligonucleotides hALAS22 (5’- CGT GTC GAC GAT GCA 
CCA TCA CCA CCA TCA CGG GAA GAG CAA GAT TGT GCA GAA G-3’) and 
r-hALAS23 (5’-AAG TGG TAA AGA TGA AGC CTG CAG CAT- 3’) as forward 
and reverse primers, respectively.  The SalI site and the codons for the six 
histidines are indicated in italics and bold, respectively, in the sequence for the 
hALAS22 primer (above). The r-hALAS23 reverse primer was designed to anneal 
to the DNA coding strand, 531 bp downstream of the BlpI site. The generated 
PCR product (1040bp) was digested with SalI and BlpI to yield a 505bp-DNA 
fragment that was subsequently subcloned into the previously digested pSD1, 
pSD2, pSD3, and pQ548X vectors using T4 DNA ligase in  ligase buffer (Thermo 
Scientific Fermentas) at 16oC. Electrocompetent BL21(DE3) cells were 
transformed by electroporation with the ligated plasmids and selected by 
spreading the transformed cells on LB agar medium containing 50 g/mL 
ampicillin. Plasmid DNA was purified from a single colony using a QiaPrep Spin 
Miniprep kit (Qiagen Inc.). The N-terminal ALAS- and histidine-encoding 
sequences were verified by DNA sequencing using the primer r-hALAS17 (5’- 
CTG GTC ATA ACT GAA GAC-3’), which anneals complementarily to the DNA 
coding strand and 208 bp downstream of the initiation and histidine codons 
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introduced in the sequences for the mature hALAS2 and XLEPP variants. The 
resulting plasmids, pEF40, pEF41, and pEF42, were used for the expression of 
histidine-tagged wild-type hALAS2, delAT, and delAGTG, respectively. 
 
Cell culture—K562 cells were maintained in RPMI-1640 culture medium 
(Mediatech, Inc.), with 10% FBS (Thermo Scientific™ HyClone™), gentamicin 
(Mediatech, Inc., 50 g/mL), penicillin (Mediatech, Inc., 60 μg/mL) and 
streptomycin (Mediatech, Inc., 100 g/mL) at 37°C in a humidified incubator with 
5% CO2. HeLa cells were maintained in DMEM with 4.5 g/L glucose, L-glutamine, 
and sodium pyruvate (Mediatech, Inc.), with 10% FBS, gentamicin (50 μg/mL), 
penicillin (60 μg/mL) and streptomycin (100 µg/mL) at 37°C in a humidified 
incubator with 5% CO2.  
 
Transient transfection of HeLa cells—On the day prior to transfection, 
HeLa cells were trypsinized and counted. Approximately 2 x 104 cells were 
seeded into each well of a 24-well plate in 0.5 mL of DMEM. Cell density was 
~30-50% confluent on the day of transfection. For each transfection, 250 ng of 
DNA was diluted into 100 μL of DMEM without serum. One μL of 
Lipofectamine™ LTX was added into the diluted DNA solution, mixed gently and 
incubated for 30-45 minutes at room temperature to form DNA-Lipofectamine™ 
LTX complexes. The DNA-Lipofectamine™ LTX complexes were added 
dropwise to each well containing cells and mixed gently by manually rocking the 
plate back and forth for a few seconds. After 4 hours of incubation with the DNA-
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Lipofectamine LTX complexes, the medium was aspirated out of each well and 
fresh DMEM with 10% FBS, gentamicin (50 g/mL), penicillin (60 μg/mL) and 
streptomycin (100 g/mL) was added to each well of cells.  Cells were incubated 
at 37°C in a CO2 incubator for 24 hours post-transfection before assaying. For 
cells treated with glycine, glycine dissolved in DMEM (1M) was added to the 
culture medium 4 hours post-transfection. 
  
Transient transfection of K562 human erythroleukemia cells—K562 cells 
were transfected with Lipofectamine™ LTX and PLUS™ Reagent, purchased 
from Invitrogen (San Jose, CA), according to the supplier’s optimized protocol for 
K562 cells. On the day of transfection, a hemocytometer and trypan blue staining 
were used to count the cells and determine culture density and viability. In a 6-
well plate, K562 cells (5 x 105 cells per well) were seeded in a 6-well plate at a 
volume of 2 mL of RPMI-1640 growth medium with 10% FBS 30 minutes prior to 
transfection. For each transfection, 2.5 μg of DNA was added into 500 μL of 
RPMI medium without serum. 2.5 μL of PLUS™ reagent (at a 1:1 ratio to DNA) 
was then added directly to the diluted DNA. After gentle mixing and a 10 minute 
incubation at room temperature, 10 μL of Lipofectamine™ LTX was added into 
the diluted DNA solution, mixed gently and incubated for 35 minutes at room 
temperature to form DNA-Lipofectamine™ LTX complexes. The DNA-
Lipofectamine™ LTX complexes were added dropwise to each well containing 
cells and mixed gently by manually rocking the plate back and forth. Cells were 
incubated at 37°C in a CO2 incubator for 24 hours post-transfection before 
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assaying. For cells treated with glycine, glycine dissolved in RPMI (1 M) was 
added to the culture medium 4 hours post-transfection. 
 
Preparation of cells for FACS and quantitation of PPIX—HeLa and K562 
cells were washed, scraped and resuspended in PBS (80 mM disodium 
hydrogen orthophosphate, 20 mM sodium dihydrogen orthophosphate, 100 mM 
sodium chloride, pH 7.5) before pipetting into BD Falcon tubes with cell strainer 
caps. Preparation of cells for FACS was done under very low light conditions (1-2 
Lux as measured by a Pyle PLMT68 light meter) in order to minimize 
phototoxicity caused by PPIX accumulation. FACS analyses were performed 
using a BD LSR II Analyzer (Becton, Dickinson, and Company) and FACSDiva 
Version 6.1.3 software. ZsGreen1 emission was measured between 515 nm and 
545 nm (530/30BP filter) when cells were excited using the 488 nm laser. In 
order to eliminate any background red fluorescence, the 633 nm-red laser was 
blocked during the collection of the PPIX emission data. PPIX emission was 
determined in the 619 nm and 641 nm range (630/22BP filter) when cells were 
excited with the 405 nm laser. Forward-scatter (FSC) versus side-scatter (SSC) 
dot plots were used to gate the whole cells and thus remove the contribution of 
the cell debris from the population being examined. A minimum of 10,000 of the 
gated whole cells were then depicted in dot plots of SSC versus ZsGreen1 
fluorescence, and the “green-fluorescent population” gate was defined based on 
untransfected HeLa cells as negative controls. Dot plots of SSC versus PPIX 
fluorescence were used to define the PPIX-accumulating cells for both the 
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“green-fluorescent” and the “non-green fluorescent” populations. The PPIX gating 
was based on the negative control for PPIX, the pIRES2-ZsGreen1 vector-
expressing cells. Normalized PPIX fluorescence values were obtained by dividing 
the mean PPIX fluorescence by the mean ZsGreen1 fluorescence for each cell 
population.  
 
Protein purification—Similarly to methods previously described (24), 
recombinant human ALAS2 and the XLEPP variants were purified from 
BL21(DE3) E. coli cells containing the overexpressed protein. BL21(DE3) cells 
harboring the expression plasmids for histidine-tagged hALAS2 were grown in 
two 125 mL flasks with 50 mL of LB medium containing 100 g/mL ampicillin at 
37 C for 8 hours. In each of eight 2 L flasks, 10 mL of bacterial culture was 
added to MOPS medium containing 100 g/mL ampicillin for a total volume of 1 L 
per flask. The bacterial cultures were grown for 16 hours at 37 C. The cells were 
then harvested by centrifugation and stored at -20 C until the day of purification.  
All purification procedures were carried out at 4 C as described previously 
(25) with minor changes. For proteins purified for activity assays, the cell pellet 
was resuspended in 30-40 mL of resuspension buffer (20 mM tricine, pH 8.0 
containing 5 mM β-mercaptoethanol, 20 µM PLP, 10% glycerol, and 0.2% Triton 
X-100). The following protease inhibitors were also added in all buffers just 
before usage: aprotinin, leupeptin, and pepstatin at 1 µg/mL, and PMSF at 10 
µg/mL. Following resuspension, the cells were homogenized and lysed by 
passing the cells twice through a French press at 10,000 psi. Cell debris was 
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removed by ultracentrifugation in a swinging bucket rotor at 104,000 x g for 1 
hour. The supernatant containing the protein was then loaded onto an affinity 
chromatography column (1.5 x 10cm) packed with HisPur  Ni-NTA resin 
(Thermo Fisher Scientific Inc.) previously equilibrated with an “equilibration 
buffer” (20 mM tricine, pH 8, containing 20 µM PLP, and 10% glycerol,).  The 
resin was subsequently washed with 100 mL of buffer A (20 mM tricine, pH 8, 
containing 5 mM β-mercaptoethanol, 20 µM PLP, and 10% glycerol), 50 mL of 
buffer A, pH 8, with 0.5 M NaCl, 50 mL of a 25 mM imidazole buffer (i.e., 25 mM 
imidazole, pH 7.2, containing 5 mM β-mercaptoethanol, 20 µM PLP, and 10% 
glycerol), and finally 50 mL of a 50 mM imidazole buffer (i.e., 50 mM imidazole, 
pH 7.2, containing 5 mM β-mercaptoethanol,  20 µM PLP, and 10% glycerol). 
The protein (either hALAS2 or XLEPP variants) was eluted with 50 mL of a 100 
mM imidazole buffer (i.e., 100 mM imidazole, pH 7.5, containing 5 mM β-
mercaptoethanol, 20 µM PLP, and 10% glycerol). The eluted protein was 
immediately concentrated in protein concentrators with a 20,000 molecular 
weight cutoff (Thermo Scientific™ Pierce™). During concentration, the buffer 
was gradually exchanged to 20 mM tricine buffer, pH 8, containing 20 µM PLP, 
and 10% glycerol. 
For the purification of proteins used in structural studies, glycerol and free 
PLP was eliminated from the buffers. Briefly, the cell pellet was resuspended in 
30-40 mL of 20mM sodium phosphate, pH 8.0, containing 300 mM sodium 
chloride, 20 µM PLP, and 0.2% Triton X-100. The supernatant containing the 
protein was then loaded onto an affinity chromatography column (1.5 x 10cm) 
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packed with HisPur  Ni-NTA resin previously equilibrated with a phosphate 
equilibration buffer (20 mM sodium phosphate, pH 7.4, 300 mM sodium chloride, 
and 10 mM imidazole).  The resin was first washed with phosphate equilibration 
buffer, followed by washes with increasing imidazole concentrations of 25 mM 
and 50 mM. The protein was eluted with 50 mL of a 150 mM imidazole buffer 
(i.e., 20 mM sodium phosphate, pH 7.4, containing 300 mM sodium chloride, 150 
mM imidazole). The eluted protein was immediately concentrated and gradually 
exchanged with 20 mM phosphate buffer, pH 8.  
Purity of the protein was assessed by SDS-PAGE. Protein concentration 
was determined by the bicinchoninic acid (BCA) assay and bovine serum 
albumin as the standard. Protein concentrations are reported on the basis of 
subunit molecular masses of 57.3 kDa, 55.0 kDa, and 57.3 kDa, for the wild-type 
hALAS2, delAT, and delAGTG variants, respectively, calculated using the amino 
acid sequences and ProtPram (26).  
 
Spectrophotometric determination of ALAS activity—ALAS steady-state 
activity was determined at 37 C using a continuous coupled enzyme assay on a 
Shimadzu UV2100 UV/Vis spectrophotometer as described previously for wild-
type ALAS (27). The ALAS steady-state kinetic parameters of wild-type hALAS2 
and delAT activities were also determined at 30 C. 
 
Thermostability Assays—ALAS2 samples were placed in a thermocycler 
and heated to the desired temperature for 3 minutes, after which the sample was 
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cooled to 37°C and used in the ALAS activity assay as described above. All 
temperatures for each enzyme variant were performed in triplicate. 
 
Acrylamide Fluorescence Quenching—Fluorescence emission spectra 
were collected on a Shimadzu RE-5301 PC spectrofluorophotometer using an 
excitation wavelength of 295 nm and protein concentrations of 2 μM in 20 mM 
phosphate buffer, pH 8.0. Blank fluorescence spectra were collected from 
samples containing all components except enzyme immediately prior to the 
measurement of samples containing enzyme and were subtracted from the 
spectra of samples containing enzyme. Acrylamide, made just prior to running 
the experiments as a 2 M stock, was added to yield final volumes in 100 µM 
increments, and the spectra were recorded after each addition. To account for a 
significant dilution of the enzyme concentration as acrylamide was added to a 
final concentration of 1 M, emission intensities were multiplied by the appropriate 
dilution factor. To obtain dynamic quenching constants for each ALAS2 variant, 
emission intensities at 330 nm were graphed against the acrylamide 
concentration in Stern-Volmer plots to linear Equation 3.1  
 
in which Fo is the fluorescence intensity without quencher, F is the fluorescence 
intensity with quencher, kq is the quencher rate coefficient, τ0 is the lifetime of the 
emissive state of tryptophan without quencher present, Q is the concentration of 
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the quencher acrylamide, and KSV is the dynamic quenching constant of 
acrylamide for the tryptophans of hALAS2. 
 
Circular dichroism (CD) spectroscopy—CD spectra were recorded using a 
JASCO J-815 spectrometer. For far-ultraviolet (UV) CD, the proteins were at 0.1 
mg/mL in 20 mM sodium phosphate, pH 8.0 in a cuvette with a 1.0 mm path 
length. Spectra covered a 260-190 nm range and were collected at 25°C and a 
scan speed of 20 nm/minute with a 0.1 nm step size and 1.0 nm bandwidth. Four 
spectra were accumulated and averaged for each sample. For near UV and 
visible CD, the proteins were prepared at 1.0 mg/mL in 20mM sodium phosphate, 
pH 8.0, in a cuvette with a 1.0 cm path length. Spectra were recorded between 
500-260 nm at 25°C at a scan speed of 20 nm/minute. Three spectra were 
accumulated and averaged for each sample. 
 
 
Results  
 Kinetic characterization of the XLEPP variants at 37°C—Steady-state 
kinetic parameters were determined with respect to substrates glycine and 
succinyl-CoA (Table 3.2) and compared to the published parameters, which were 
acquired at 30°C for wild-type hALAS2 and the XLEPP variants (22). The 
catalytic constant (kcat) value determined for the wild-type enzyme was 0.27 s
-1, 
and the Km values for glycine and succinyl-CoA were 12.6 mM and 6.1 µM, 
respectively. DelAT, which exhibited a kcat value 3-fold higher than that of wild-
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type hALAS2 at 30°C (22), had a 3-fold kcat value than the wild-type hALAS2 at 
37°C, indicating that delAT has remarkably different thermodynamic properties 
and may be less stable than wild-type hALAS2. The kcat values for delAGTG and 
Q548X were increased in comparison to the wild-type enzyme by 1.7-fold and 
1.4-fold, respectively. DelAGTG exhibited increased affinities for both glycine and 
succinyl-CoA, while Q548X only had an increased affinity for succinyl-CoA. Of 
the XLEPP variants tested alongside wild-type hALAS2, delAGTG, with its 
extended C-terminus, generated the greatest effects on kcat values and substrate 
affinities. 
 
 Table 3.2. Kinetic parameters for human wild-type ALAS2 and XLEPP 
variant enzymes at 37°C. 
 
 
 HeLa and K562 cells expressing XLEPP variants accumulate more PPIX 
than cells expressing wild-type hALAS2—The extent to which the XLEPP 
variants might lead to PPIX accumulation was evaluated ex vivo in HeLa and 
K562 cells.  In HeLa cells, in comparison to expression of wild-type hALAS2, 
delAT, delAGTG, and Q548X increased PPIX by 2.9-fold (p<0.05), 3.6-fold 
Enzyme        
    
 (sec-1) (µM) (sec-1µM-1) (mM) (sec-1mM-1) 
Wild-type  0.27 ± 0.02 6.1 ± 3.7 0.05 ± 0.03 12.6 ± 0.2 0.021 ± 0.002 
DelAT  0.09 ± 0.01 2.5 ± 1.3 0.04 ± 0.02 18.0 ± 7.6 0.005 ± 0.003 
DelAGTG  0.45 ± 0.05 3.6 ± 2.0 0.13 ± 0.08 4.2 ± 1.3 0.108 ± 0.045 
Q548X 0.39 ± 0.04 4.2 ± 2.2 0.09 ± 0.05 22.0 ± 3.8 0.018 ± 0.005 
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(p<0.01), and 3.7-fold (p<0.01), respectively (Figure 3.1). In K562 cells, delAT, 
delAGTG, and Q548X increased PPIX by 1.6-fold (p<0.05), 1.6-fold (p<0.05), 
and 2.1-fold (p<0.01), respectively. Expression of delAT, delAGTG, or Q548X 
resulted in significantly increased PPIX accumulation in mammalian cells in 
comparison to expression of wild-type hALAS2, indicating that the XLEPP 
variants are stable in the cellular environment.  
 
 Glycine supplementation of the culture medium only increases PPIX 
accumulation in HeLa cells expressing XLEPP variants with an increased affinity 
for glycine—Since the XLEPP variants have variable affinities for glycine (Table 
3.2), we set out to examine if glycine has a similar effect in mammalian cells 
expressing XLEPP variants. In cells expressing wild-type hALAS2, 
supplementation of the media with 100 mM glycine increased the PPIX by 2-fold 
(p<0.05) and in cells expressing delAGTG, PPIX increased by 1.5-fold (p<0.01) 
(Figure 3.2). However, the effect of glycine supplementation on cells expressing 
delAT and Q548X did not reach statistical significance (p>0.05). These data 
corroborate the steady-state kinetic characterizations at 37°C that indicate that 
delAGTG, in contrast to delAT and Q548X, has an increased affinity for the 
glycine substrate.  
 
The XLEPP variants are more thermostable than wild-type hALAS2—To 
better understand the relationship between kinetics and temperature on the 
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XLEPP variants, we placed the enzymes at a range of temperatures prior to 
testing catalytic activity. Interestingly, the variants, especially delAT, were more 
 
Figure 3.1. Expression of XLEPP variants in mammalian cells results in 
accumulation of PPIX. HeLa cells are indicated by vertical-striped bars, while K562 
cells are represented by checkered bars. The hALAS2 variants shown are wild-type 
enzyme (blue), delAT (purple), delAGTG (pink), and Q548X (green). Mean PPIX 
fluorescence values are representative of three separate experiments ± standard 
deviation (*p<0.05 and **p<0.01, Student’s t-test) [a.u., arbitrary units].  
 
 
sensitive to slight temperature increases up to 45°C (Figure 3.3). However, at 
temperatures above 50°C, wild-type hALAS2 lost all measurable activity whereas 
the delAT and delAGTG variants retained 7% and 11 % of their initial activity, 
respectively, at 70°C. The K1/2 values, defined as the observed temperatures at 
which the enzymes lost 50% of their initial activity, were 48.6°C, 52.5°C, 49.9°C, 
and 51.4°C, for wild-type hALAS2, delAT, delAGTG, and Q548X, respectively. 
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Figure 3.2. Glycine supplementation of the culture medium only increases PPIX 
accumulation in cells expressing XLEPP variants with an increased affinity for 
glycine. Plus (+) signs indicate samples in which the culture medium was supplemented 
with 100 mM glycine, and minus (-) signs indicate samples in which no glycine was 
added. The hALAS2 variants shown are wild-type hALAS2 (blue), delAT (purple), 
delAGTG (pink), and Q548X (green). Mean PPIX fluorescence values are representative 
of three separate experiments ± standard deviation (*p<0.05 and **p<0.01, Student’s t-
test) [a.u., arbitrary units].  
 
The XLEPP variants undergo significant changes in secondary structure 
upon succinyl-CoA binding—Structural changes among wild-type hALAS2 and 
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the XLEPP variants were evaluated using CD spectroscopy from 260 nm to 190 
nm. ALAS undergoes a conformational change upon binding of its substrates 
(28-31), and thus we examined the change in secondary structure of wild-type 
hALAS2 and the XLEPP variants upon addition of succinyl-CoA. The CD spectra 
for wild-type hALAS2 and the XLEPP variants indicated presence high degree of 
α-helical content, consistent with the crystal structure of R. capsulatus ALAS 
(32,33) (Figure 3.4). Binding of succinyl-CoA resulted in a very minor change in 
secondary structure for wild-type hALAS2 (Figure 3.4A), but caused more 
significant alterations in the secondary structure of the XLEPP variants, as noted 
by the increases in mean residue molar ellipticity at 210 nm and 222 nm (Figure 
3.4B-D). 
 
 
 
Figure 3.3. Thermostability profiles vary for hALAS2 and XLEPP variants. Data are 
averages of three independent experiments and are fit to the sigmoidal equation y= 
a/(1+e(-(x-x0)/b)). The observed K1/2 values were 48.6°C, 52.5°C, 49.9°C, and 51.4°C, for 
wild-type hALAS2 (blue), delAT (green), delAGTG (pink), and Q548X (purple), 
respectively.  
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Figure 3.4. Circular dichroism spectra of hALAS2 and the XLEPP variants in the 
far-UV nm region. (A) Wild-type hALAS2, (B) delAT, (C) delAGTG, (D) Q548X. The 
spectra for the holoenzymes are shown in each panel in solid lines, and the spectra for 
the enzymes in the presence of 50 μM succinyl-CoA are in dotted lines. The 
concentrations of enzyme were 0.1 mg/mL in 20 mM phosphate buffer, pH 8.0.  
 
The tertiary structures and PLP-binding properties of the XLEPP variants 
are distinct from those of wild-type hALAS2—Possible structural differences 
between hALAS2 and the XLEPP variants were also analyzed by quantifying the 
concentration of acrylamide required to quench the intrinsic fluorescence of 
buried tryptophan residues in the enzymes (Figure 3.5). Dynamic quenching 
constants were calculated using Stern-Volmer plots of the resultant data, as 
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defined by Equation 1, for wild-type hALAS2, delAT, delAGTG, and Q548X of 
1.42 M-1, 5.29 M-1, 1.92 M-1, and 2.54 M-1, respectively. The increased KSV values 
observed with the XLEPP variants indicated that the tryptophans of the variants, 
especially those of delAT, were more accessible to the aqueous solvent than 
those of wild-type hALAS2. 
 
 
Figure 3.5. Stern-Volmer plots displaying fluorescence quenching of buried 
tryptophan residues in hALAS2 variants. Wild-type hALAS2, delAT, delAGTG, and 
Q548X are shown in blue, green, pink, and purple, respectively. In each case the 
enzyme concentration was 2 µM, and buffer was 20 mM phosphate, pH 8.0. 
 
The differences in tryptophan fluorescence as observed by acrylamide 
fluorescence quenching were further investigated by using near-UV CD and CD 
in the visible light region, to analyze tertiary structure and the structural integrity 
of the PLP binding site, respectively. Each of the XLEPP variants had a distinct 
CD spectrum in the near UV region, indicating slight changes in the tertiary 
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structure as visualized by changes in mean residue molar ellipticity bands at 
wavelengths corresponding to aromatic residues (260-295 nm) (Figure 3.6A). In 
the visible region, intense bands at 330 nm, indicative of PLP bound in the active 
site of ALAS2 were observed with the delAGTG and Q548X XLEPP variants, 
(Figure 3.6B). Wild-type hALAS2 and all three XLEPP variants displayed intense 
molar ellipticity bands around 430 nm, which also signified PLP bound in the 
active site. 
  
 
Figure 3.6. Circular dichroism spectra in the near-UV and visible region. (A) Wild-
type hALAS2, (B) delAT, (C) delAGTG, (D) Q548X are shown in blue, green, pink, and 
purple, respectively. The concentrations of enzyme were 1.0 mg/mL in 20 mM 
phosphate buffer, pH 8.0.  
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Succinyl-CoA binding caused secondary structural changes in the XLEPP 
variants to a greater extent than wild-type hALAS2 (Figure 3.4).  CD was used to 
further assess the effects of succinyl-CoA binding on both the tertiary structures 
and integrity of the PLP-binding sites of the purified enzymes. While the tertiary 
structures of wild-type hALAS2 and delAT were only slightly changed upon 
binding of succinyl-CoA (Figure 3.7A-B), delAGTG and Q548X displayed right-
shifted 330 nm bands and changes in positioning of the aromatic amino acids 
(Figure 3.7C-D), suggesting these variants undergo significant changes in the 
positioning of PLP in the active site. 
 
  
Figure 3.7. Circular dichroism spectra in the near-UV and visible region in the 
presence of 50 μM succinyl-CoA. (A) Wild-type hALAS2, (B) delAT, (C) delAGTG, (D) 
Q548X are shown in blue, green, pink, and purple, respectively. The concentrations of 
enzyme were 1.0 mg/mL in 20 mM phosphate buffer, pH 8.0.  
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Discussion 
Multiple molecular mechanisms, including changes in enzyme kinetics, 
stability, rate of degradation, structure, and/or interaction with the regulatory β-
subunit of the ATP-specific isoform of succinyl-CoA synthetase (SCS-βA) can 
contribute to the decreases in ALAS2 activity observed in XLSA, (16,34), and 
each of these mechanisms might also be operative in the gain-of-function 
mutations resulting in XLEPP. Previously we (22) and others (21,23) have 
demonstrated that purified recombinant XLEPP variants are more active than the 
wild-type hALAS2, at least at 30°C. In this study, we report that the XLEPP 
variants differ in their substrate affinities, thermostabilities, secondary structures 
upon substrate binding, tertiary structures, and PLP-binding site integrity.  
Deleting the C-terminal 33 amino acids of hALAS2, which are conserved 
in higher eukaryotes but not present in prokaryotes, results in increased catalytic 
activity (21). Furthermore, when this variant is expressed in HEK293 human 
embryonic kidney cells, there is an increase in protein stability as shown by lack 
of degradation in comparison to wild-type hALAS2 (21). In addition to the 
truncated variant, two XLSA variants with point mutations near the C-terminus, 
V562A and M567I, have been cloned and reported to have altered activities and 
stabilities (21). Interestingly, the purified V562A enzyme exhibits higher catalytic 
activity, but has a shorter half-life in transfected cells, while in contrast, the 
purified M567I enzyme loses 75% of catalytic activity in comparison to wild-type 
hALAS2, but has an extended half-life when expressed in human embryonic  
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Figure 3.8. The citric acid cycle and heme synthesis. ALAS activity couples heme 
production to aerobic respiration via common use of succinyl-CoA. The common usage 
of succinyl-CoA as substrate implies close proximity of the 2 enzymes in vivo. 
 
kidney (HEK293) cells. These results emphasize that the hALAS2 C-terminal 
extension is clearly significant in determining the activity and stability of the 
mammalian enzyme. 
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The C-terminus is also important for protein-protein interaction of hALAS2 
with SCS- A (16) (Figure 3.8). Wild-type hALAS2 and two XLSA variants, R411C  
and M426V, associate with SCS- A, while another XLSA variant, D190V, loses 
its ability to interact with SCS- A (34).  Two XLSA variants with mutations near 
the C-terminus, M567V and S568G, and a C-terminal truncated variant (F557X) 
were reported to have normal or enhanced activity and stability, but none of them 
bound to SCS- A, whereas wild-type hALAS2 bound strongly (16). Intriguingly, 
delAT also leads to a mutation at the same methionine residue, M567E, which is 
followed by a premature stop codon. Unlike the M567V variant, delAT still 
strongly binds SCS- A (16). These data, along with studies on other variants with 
mutations at the C-terminus (16), imply that the interaction of ALAS2 and SCS-
A is essential for full activity in vivo, and that one region vital for this interaction 
lies between R559 and S568. In a cellular environment, the interaction of the 
XLEPP variants and SCS- A is likely critical for their increased activity and 
resulting PPIX accumulation (Figures 3.1 and 3.2). 
The kcat values for the XLEPP variants measured using purified 
recombinant enzyme, determined at 30 C, ranged from 3- to 3.4-fold greater than 
that of wild-type hALAS2 and the specificity constants toward succinyl-CoA 
( ) were increased up to fourteen-fold (22). The “gain-of-function 
domain,” was previously concluded to extend over a minimum of 33 amino acids 
of ALAS2 between residues G544 and G576 (22). Here we determined the kcat 
values for the XLEPP variants at 37°C, as experiments with hyperactive mouse 
ALAS2 variants have shown that activation energies among variants can vary 
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widely, and elevated activity at lower temperatures does not always equate to 
elevated activity at physiological temperature (35). The kcat value for wild-type 
hALAS2 exhibited a 9-fold increase in activity when the temperature increased 
from 30°C to 37°C, whereas the kcat value for delAT remained similar between 
30°C (22) and 37°C (Table 3.2). The kcat value for delAGTG increased by 4-fold 
and for Q548X increased by 4.3-fold. It is possible that the interaction of ALAS2 
with the SCS-βA provides stabilization for ALAS2 in vivo, which could explain 
why we found delAT to be less active in vitro at 37°C in the absence of SCS-βA, 
but more active when HeLa cells and K562 cells were transfected with an 
expression plasmid for delAT than wild-type hALAS2. 
The purified XLEPP variants are more stable at temperatures above 55°C 
(Figure 3.3), indicating that the increased thermostabilities of the variants is 
independent of interaction with SCS and proteolytic susceptibility. These results 
led us to examine the secondary and tertiary structures of wild-type hALAS2 in 
relation to those of the XLEPP variants using CD and fluorescence 
spectroscopies. The far-UV spectra for hALAS2 and the XLEPP variants are 
indicative of a predominantly α-helical structure, and are similar among the 
variant and wild-type proteins (Figure 3.4). However, upon addition of succinyl-
CoA, the XLEPP variants undergo a much larger structural rearrangement than 
the wild-type enzyme. These enhanced structural changes may explain the 
increased affinities of the XLEPP variants for succinyl-CoA. 
CD spectral signals in the near-UV region arise from the aromatic amino 
acids, and the intensities of these signals are sensitive to the tertiary structure of 
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the protein (32). Generally, tryptophan shows a spectral band close to 290 nm, 
tyrosine a band between 275 and 282 nm, with a shoulder at longer wavelengths 
often obscured by bands due to tryptophan, and phenylalanine shows weaker but 
sharper bands between 255 and 270 nm (32). The actual shape and magnitude 
of the near-UV CD spectrum of a protein will depend on the number of each type 
of aromatic amino acid present, their mobility, the nature of their environment (H-
bonding, polar groups and polarizability) and their spatial disposition in the 
protein (32). Notably, wild-type hALAS2 and each XLEPP variant differ in the 
number of specific aromatic amino acids. Wild-type hALAS2 has 5 tryptophans, 
15 tyrosines, and 26 phenylalanines, whereas delAT is missing 1 tryptophan, 3 
tyrosines, and 1 phenylalanine. DelAGTG lacks the same aromatic amino acids 
as delAT, but has a tryptophan in its extended C-terminus, and Q548X lacks an 
additional 2 phenylalanines in comparison to delAT (Table 3.1). Each variant has 
a distinct near-UV spectrum that differs from that of the wild-type enzyme not 
only in intensity, but also in shape (Figure 3.6). The divergent tertiary structures 
of the variants (Figures 3.5 and 3.6) might help explain why the variants are more 
active than wild-type hALAS2. For instance, if the kcat value for hALAS2 is 
dependent on the conformation adopted by the protein, as has been shown to be 
the case for mouse ALAS2 (2), a looser, more conformationally dynamic 
structure in the XLEPP variants could result in higher activity.  However, in the 
absence of high-resolution 3-dimensional structures of wild-type hALAS2 and the 
XLEPP variants, it is difficult to postulate exactly what these structural changes 
are and precisely why they are associated with increased activity. 
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Enzyme cofactors that absorb in the visible region of the electromagnetic 
spectrum, such as PLP, show CD signals in the visible region only when bound 
to their protein partner in sites which confer chirality. These CD signals are thus 
excellent indicators of the integrity of the cofactor-binding site (32). PLP-
dependent absorption maxima at 330 and 420 nm are considered to be 
characteristic of different ionization states of the internal aldimine bond between 
the PLP and the ALAS, corresponding to the unprotonated and protonated forms, 
respectively (36-39). The binding of delAGTG and Q548X to PLP results in 
intense spectral bands around 330 nm that are not evident in the spectra of the 
wild-type hALAS2 or delAT (Figure 3.7A-B). The spectra of delAGTG and Q548X 
also display slightly higher intensity spectral bands between 420-430 nm (Figure 
3.7C-D). PLP thus appears to bind these variants more tightly in both ionization 
states, which is again consistent with the enhanced activity of these variants in 
vivo. Upon addition of succinyl-CoA, the 330 nm-band observed in the spectra of 
the delAGTG and Q548X variants is red-shifted to a broader band from 340-400 
nm, indicating a substantial change in the chirality of PLP in the active site when 
succinyl-CoA is bound. 
In conclusion, these studies represent the first structural evaluations of the 
XLEPP variants of hALAS2. We provide evidence that XLEPP can be modeled in 
cell culture, and this model may aid in testing for direct action of potential 
therapeutics on hALAS2. We also found that the XLEPP variants are more 
thermostable, undergo more extensive conformational changes upon the addition 
of succinyl-CoA, and differ in terms of tertiary structure and PLP binding. Future 
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studies should aim to solve the crystal structure of hALAS2 and to discover 
effective therapeutics for the treatment of XLEPP. 
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CHAPTER 4: ISONIAZID INHIBITS HUMAN ERYTHROID  
5-AMINOLEVULINATE SYNTHASE 
 
 
Abstract 
 
Mutations in the C-terminus of human erythroid 5-aminolevulinate 
synthase (hALAS2) can result in two very different diseases, X-linked 
sideroblastic anemia (XLSA) and X-linked erythropoietic protoporphyria (XLEPP). 
XLSA patients have hALAS2 mutations that decrease activity, while mutations 
associated with XLEPP result in a gain-of-function of hALAS2. XLEPP has only 
recently been characterized, and thus there are no specific treatments. One 
potential treatment involves the use of the antibiotic isonicotinic acid hydrazide 
(isoniazid, INH), commonly used to treat tuberculosis, as INH can cause 
sideroblastic anemia as a side-effect. INH has traditionally been thought to cause 
anemia by limiting PLP availability to hALAS2 via direct inhibition of pyridoxal 
kinase, and reacting with pyridoxal to form pyridoxal isonicotinoyl hydrazone. We 
postulated that in addition to PLP-dependent inhibition of hALAS2, INH directly 
acts on hALAS2. Using FACS and confocal microscopy, we show here that INH 
reduces protoporphyrin IX accumulation in HeLa cells expressing either wild-type 
human hALAS2 or XLEPP variants. In addition, PLP and PMP restored cellular 
hALAS2 activity in the presence of INH. Kinetic analyses with purified hALAS2 
demonstrated non-competitive or uncompetitive inhibition with an apparent Ki of 
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1.5 µM. Circular dichroism studies revealed that INH triggers structural changes 
in hALAS2 that interfere with the association of hALAS2 with its PLP cofactor. 
These studies demonstrate that hALAS2 can be directly inhibited by INH,  
provide insight into the mechanism of inhibition, and support the prospective use 
of INH in treating patients with XLEPP and potentially other cutaneous 
porphyrias. 
 
Introduction 
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) is a pyridoxal 5’-
phosphate (PLP)- dependent enzyme that catalyzes the first and rate-limiting 
reaction in heme biosynthesis, the condensation of glycine and succinyl-CoA to 
form 5-aminolevulinate (ALA), CoA, and CO2 (1-3). Two genes, ALAS1 and 
ALAS2, encode the housekeeping and erythroid-specific ALAS isoforms, 
respectively (4,5). ALAS2 is expressed specifically in developing erythrocytes, 
where high levels of heme are required for hemoglobin production. Mutations in 
human ALAS2 (hALAS2) are associated with two different diseases, X-linked 
sideroblastic anemia (XLSA; MIM# 300751) (6,7) and X-linked erythropoietic 
protoporphyria (XLEPP; MIM# 300751) (8,9). XLSA patients have mutations in 
hALAS2 that result in decreased activity (7,10); approximately 50% of these 
patients are pyridoxine-responsive (10-12). Mutations associated with XLEPP 
have only been observed in exon 11, which encodes the C-terminus, and result 
in a gain-of-function of hALAS2 (9). Accordingly, a “gain-of-function” domain has 
been identified in the C-terminus of hALAS2 with a minimal length of 33 amino 
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acids, ranging from G544 to G576 (13). XLEPP patients experience extreme, 
painful photosensitivity due to porphyrin accumulation in the skin and, in some 
cases, abnormal liver function that can lead to liver failure (9). XLEPP has only 
recently been characterized, as patients had been misdiagnosed with 
erythropoietic protoporphyria (EPP), which is most commonly caused by 
mutations in ferrochelatase, the final enzyme of heme biosynthesis (9). 
Interestingly, administration of the antibiotic isonicotinic acid hydrazide 
(isoniazid, INH), which has been widely used for the treatment of tuberculosis, 
induces sideroblastic anemia in some patients (6,14-16). INH has been proposed 
to cause sideroblastic anemia through two mechanisms: inhibition of pyridoxal 
kinase activity (17,18)  or INH reaction with pyridoxal to form an inactive 
pyridoxal hydrazone (19,20). Both mechanisms result in reduced PLP levels, and 
thereby lower hALAS2 activity. In 1979, Konopka and Hoffbrand tested the effect 
of isoniazid on hALAS2 in erythrocyte homogenates from normal bone marrow 
and found that INH inhibited the hALAS2 activity dose-dependently (21). 
Additionally, they examined bone marrow from a patient with INH-induced 
sideroblastic anemia and found that hALAS2 activity of bone marrow could be 
restored to normal levels in vitro with supplementation of PLP (21). Based on 
these findings the investigators concluded that INH functioned as a pyridoxine 
antagonist, and thus indirectly inhibited hALAS2 (21).  
INH is currently in a clinical trial enrolling EPP and XLEPP patients, (NCT 
ID# NCT01550705), with the rationale that limiting vitamin B6 cofactor may 
reduce hALAS2 activity, thereby dereasing the amount of PPIX accumulation, but 
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the effect of INH on purified hALAS2 has not been reported. Since there are at 
least 56 different human genes known to encode PLP-dependent enzymes (22), 
and yet hALAS2 can apparently be selectively inhibited during INH treatment for 
tuberculosis, we hypothesized that INH might directly bind to and inhibit hALAS2. 
This hypothesis supports INH as a very logical treatment for cutaneous 
porphyrias like EPP and XLEPP, caused by disruption of heme biosynthesis and 
subsequent porphyrin accumulation.  
Here we report that the results of cell culture studies support previous 
conclusions on the effect of INH on hALAS2 activity and the ability of PLP to 
reverse INH inhibition of hALAS2. Our studies using purified recombinant 
hALAS2 showed that INH can alter the tertiary structure of hALAS2, decrease 
the binding of PLP to hALAS2, and directly inhibit hALAS2 activity. We provide 
insight into its direct mechanism of inhibition and offer further evidence for using 
INH to treat patients with XLEPP and other cutaneous porphyrias. 
 
Materials  
Reagents—Aprotinin, pepstatin, leupeptin, PMSF, ampicillin, β-
mercaptoethanol, pyridoxal 5’-phosphate, succinyl-CoA, thiamine pyrophosphate, 
and NAD+ were obtained from Sigma-Aldrich Chemical Company. Glucose, 
glycerol, acetic acid, methanol, glycine, disodium hydrogen orthophosphate, 
sodium dihydrogen orthophosphate, DMSO, EDTA, MOPS, tryptone, yeast 
extract, sodium chloride, tricine, ammonium sulfate, and potassium hydroxide 
were purchased from Fisher Scientific. Centricon concentrators were from 
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Millipore. Sodium dodecyl sulfate polyacrylamide gel electrophoresis reagents 
and Phusion DNA Polymerase were acquired from Thermo Scientific. 5-
Aminolevulinic acid hydrochloride, isonicotinic acid hydrazide, and pyrazinamide 
were purchased from Acros Organics. 1, 1-Dimethylhydrazine was purchased 
from SPEX Certiprep group. BmtI, SalI, BlpI, and BamHI restriction enzymes 
were obtained from New England BioLabs, Inc. Gentamicin sulfate and RPMI-
1640 culture medium were procured from Mediatech, Inc. Oligonucleotides were 
synthesized by Integrated DNA Technologies. T4 DNA ligase and ligase buffer 
were obtained from Thermo Scientific Fermentas and a bicinchoninic acid protein 
determination kit was purchased from Thermo Scientific Pierce. 
 
Methods 
Plasmids for mammalian expression and protein purification—For 
expression plasmids used in the transfection of mammalian cells, the wild-type 
precursor ALAS2 cDNA (GenBank: X56352.1) was subcloned into the multiple 
cloning site of the pIRES2-ZsGreen1 vector (purchased from Clontech 
Laboratories, Inc. Mountain View, CA) using the BmtI and BamHI restriction sites 
as described previously (Chapter 3, pages 109-112). The resulting plasmid was 
named pEF27. For the mammalian expression plasmids encoding the precursor 
XLEPP variants, the cDNAs encoding the mutated hALAS2 C-termini were 
subcloned into pEF27 and the resulting plasmids were named pEF28 and 
pEF29, encoding delAT and delAGTG, respectively, as described previously 
(Chapter 3, pages 110-112). To purify hALAS2 and the XLEPP variant proteins 
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using nickel affinity chromatography, we added six histidine codons to the cDNA 
sequence encoding the mature N-terminus of hALAS2, and subcloned the 
digested PCR products into plasmids expressing wild-type hALAS2 and 
delAGTG, as described previously (Chapter 3, pages 111-112). The resulting 
plasmids, pEF40 and pEF42, were used for the expression of histidine-tagged 
wild-type hALAS2 and delAGTG, respectively. 
Cell culture—Human cervical carcinoma (HeLa) cells were maintained in 
DMEM with 4.5 g/L glucose, L-glutamine, and sodium pyruvate (Mediatech, Inc.), 
with 10% fetal bovine serum (FBS) (Thermo Scientific™ HyClone™), gentamicin 
(Mediatech, Inc.; 50 μg/mL), penicillin (Mediatech, Inc.; 60 μg/mL) and 
streptomycin (Mediatech, Inc.; 100 g/mL) at 37°C under 5% CO2 in a humidified 
incubator.  
Transient transfection of HeLa cells—HeLa cells were transfected using 
DNA-Lipofectamine™ LTX transfection reagent as previously described (Chapter 
3, page 112). For cells treated with INH, INH dissolved in DMSO (10 mg/mL) was 
added to the culture medium 24 hours post-transfection to allow for 
protoporphyrin IX (PPIX) accumulation caused by hALAS2 expression, as 
described with murine ALAS2 (E. J. Fratz, G. A. Hunter, and G. C. Ferreira, 
unpublished observations). As a control, DMSO (10 mg/mL) was added to non-
transfected and transfected cells in culture medium at the same time point (i.e., 
24 h). Pyridoxine-HCl, PLP, and pyridoxamine-5’-phosphate (PMP) were 
dissolved in DMEM (10 mg/mL) and added to the culture medium 24 hours post-
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transfection. The final pyridoxine, PLP and PMP concentrations were each 100 
μg/mL in all experiments.  
 
Preparation of cells for FACS and quantitation of PPIX—HeLa cells were 
prepared for FACS and PPIX was quantitated as previously described (Chapter 
3, pages 114-115).  
 
Confocal fluorescence microscopy—HeLa cells were grown in 
Thermoscientific™ Nunc™ Labtek™ sterile 4-well chambered coverglass until 
50% confluent, and then transfected as described above. Twenty-four hours 
later, the culture medium was supplemented with INH to yield final 
concentrations of 100 μg/mL or 500 μg/mL. After an additional twenty-four hours, 
and immediately before obtaining confocal fluorescence microscopy images of 
the cells, the medium was removed from the wells and the cells were washed 
with PBS three times. Live cell imaging was performed using a 3i-Olympus 
spinning disk confocal microscope operated by Slidebook 5 software and 
equipped with a Photometrics Evolve EMCCD camera. The filter block used 
consisted of a 350/50 nm excitation filter, a BS400 beamsplitter, and a 630/75 
nm emission filter.  
 
Protein purification—Recombinant human ALAS2 and the XLEPP variants 
were purified from BL21(DE3) E. coli cells containing the overexpressed protein 
as described previously (Chapter 3, pages 115-117). Purity of the protein was 
148 
 
assessed by SDS-PAGE and protein concentration was determined by the 
bicinchoninic acid (BCA) assay and bovine serum albumin as the standard as 
described previously (Chapter 3, page 117). 
 
ALAS colorimetric activity assay—ALAS activity was determined 
according to the method of Lien and Beattie (23) with minor modifications. Prior 
to the activity assay, purified recombinant wild-type hALAS2 in 25 mM HEPES, 
pH 7.2, containing 10% glycerol, was incubated with INH (0-1 mM), for 15 
minutes at 37°C. After the addition of the succinyl-CoA and glycine substrates, 
the reactions proceeded, for 10 minutes at 37°C. The final concentrations of 
ALAS, succinyl-CoA and glycine were 1.5 µM, 100 μM and 100 mM for each 
assay. For the PLP-dependence assays, INH was first incubated with PLP for 15 
minutes at 37°C and then the purified recombinant wild-type hALAS2, which is 
PLP-bound, was added for a 15 minute incubation at 37°C before beginning the 
ALAS activity assay as described above. The concentrations of added PLP 
ranged from 0 μM to 40 μM. For the glycine competition assays, ALAS2 activity 
was determined using glycine concentrations ranging from 10 mM to 150 mM, 
and INH concentrations from 0 μM to 100 μM. Succinyl-CoA and hALAS2 
concentration were held constant at 100 μM and 1.5 μM, respectively. To 
determine the apparent Vmax and Km values for glycine, and the apparent Ki for 
INH, the data were first fit using Sigmaplot graphing software to Equation 4.1 
(24), 
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where y is the activity as measured by rate of ALA formation, x is either the 
concentration of glycine or INH, and Kx is either the apparent Ki for INH or Km for 
glycine. From these primary plots, the apparent maximal velocities were in turn 
used to construct secondary plots defining Vmax and Ki values. In addition, the 
glycine competition data were independently analyzed using Dynafit model 
discrimination software (25,26) to compare competitive, mixed, and partial 
inhibitory mechanisms. For illustration purposes, glycine competition data were 
evaluated using a Lineweaver-Burke plot to display the nature of the inhibition. 
Also for illustration purposes, the raw data were fit using Sigmaplot graphing 
software to a sigmoidal Equation 4.2 
 
                                        
(4.2) 
where y is the percentage of ALAS activity loss and x is log of the INH 
concentration. 
 
Circular dichroism (CD) spectroscopy—CD spectra were recorded using a 
JASCO J-815 spectrometer as described previously (Chapter 3, page 119). 
 
Results 
 
(4.1) 
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INH reduces PPIX accumulation in HeLa cells expressing wild-type 
hALAS2 and XLEPP variants—To test the ability of INH to reduce ALAS2 activity 
and PPIX production in cell culture, we transfected HeLa cells with expression 
plasmids encoding wild-type hALAS2 (WT) and two XLEPP variants, delAT and 
delAGTG, which have increased ALAS activity. At a concentration of 5 g/mL, 
INH did not cause a significant decrease in PPIX fluorescence, and thus PPIX 
accumulation, in cells expressing WT, delAT, or delAGTG (Figure 4.1). An INH 
concentration of 50 g/mL was sufficient to decrease PPIX levels in delAGTG-
expressing cells (p<0.05), and INH concentrations of 100 g/mL and 200 g/mL 
 
Figure 4.1. INH reduces PPIX accumulation in HeLa cells expressing wild-type 
hALAS2 and XLEPP variants. Wild-type hALAS2 (WT)-, delAT-, and delAGTG-
expressing HeLa cells were treated with 0, 5, 50, 100, or 200 µg/mL INH. Mean PPIX 
fluorescence values are representative of three separate experiments ± standard 
deviation (*p<0.05 and **p<0.01, Student’s t-test). [a.u., arbitrary units].  
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further decreased the amount of PPIX accumulated by 36% and 53%, 
respectively  (p<0.01). For WT-expressing cells, INH concentrations of 100 
g/mL and 200 g/mL resulted in decreased PPIX accumulation (p<0.01), and 
delAT-expressing cells required an INH concentration of 200 g/mL to reduce 
PPIX production and accumulation (p<0.05). 
 
INH reduces PPIX accumulation in both HeLa cells expressing delAGTG 
and those adjacent to delAGTG-expressing HeLa cells—To examine the PPIX 
accumulation and the effect of the INH treatment in individual cells, we used 
confocal fluorescence microscopy to analyze ZsGreen1 fluorescence and PPIX 
fluorescence. We chose to monitor delAGTG expression because it resulted in 
the highest PPIX accumulation and largest percent decrease in PPIX when 
treated with INH (Figure 4.1). HeLa cells that were not transfected (Figure 4.2A) 
and HeLa cells that were transfected with the pIRES2-ZsGreen1 vector plasmids 
(Figure 4.2B) were used as controls for no PPIX fluorescence and ZsGreen1 
fluorescence, respectively. In delAGTG-expressing cells, PPIX fluorescence was 
evident in nearly all cells, even though only approximately 25% of cells 
expressed ZsGreen1 and delAGTG (Figure 4.2C). When delAGTG-expressing 
cells were treated with either 100 or 500 g/mL INH, PPIX was visibly decreased 
in all cells (Figure 4.2D and 4.2E). 
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INH inhibition of ALAS2 activity is not affected by pyridoxine—Since the 
two described mechanisms of INH inhibition of ALAS2 are PLP-dependent, and 
oral pyridoxine can be effective in treating sideroblastic anemia acquired from  
 
Figure 4.2. INH reduces PPIX accumulation in both HeLa cells expressing 
delAGTG and those adjacent to delAGTG-expressing HeLa cells. Rows 1-4 of each 
panel correspond to the images of 1. superimposed bright-field and fluorescence, 2. 
green fluorescence 3. red fluorescence, and 4. overlaid red and green fluorescence, 
respectively. (A) Non-transfected HeLa cells. (B) HeLa cells transfected with pIRES2-
ZsGreen1. (C) HeLa cells transfected with pEF29, which encodes both ZsGreen1 and 
delAGTG. (D) HeLa cells transfected with pEF29, which encodes both ZsGreen1 and 
delAGTG, treated with INH (100 μg/mL) for 24-hours. (E) HeLa cells transfected with 
pEF29, which encodes both ZsGreen1 and delAGTG, treated with INH (500 μg/mL) for 
24-hours. “Control” refers to non-transfected HeLa cells. 
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prolonged INH treatment, we postulated that pyridoxine supplementation of the 
cell culture medium could reverse the INH inhibition of ALAS2. Pyridoxine (100 
g/mL) did not affect the PPIX levels in WT-, delAT-, or delAGTG-expressing 
cells (p>0.1) (Figure 4.3). In cells treated with INH (100 g/mL), pyridoxine also 
did not exhibit any effects on PPIX fluorescence (p>0.1), indicating that the 
addition of pyridoxine is not sufficient to overcome the INH effect on ALAS2 
activity. 
 
 
FIGURE 4.3. INH inhibition of PPIX accumulation in HeLa cells expressing either 
wild-type hALAS2 or XLEPP variants is not affected by pyridoxine. Mean PPIX 
fluorescence values are representative of three separate experiments ± standard 
deviation [a.u., arbitrary units]. 
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PLP and PMP reduce the effect of INH on ALAS2 inhibition—We next 
examined whether supplementation of the cell culture medium with PLP or PMP 
could reverse the INH inhibition of ALAS2 activity. In contrast to pyridoxine, both 
PLP and PMP (100 g/mL) restored ALAS2 activity of INH-inhibited delAT and 
delAGTG-expressing HeLa cells (p<0.05) (Figure 4.4). A similar trend was seen 
in WT-expressing cells, but the changes did not reach statistical significance 
(p>0.05). 
 
FIGURE 4.4. Either PLP or PMP supplementation of the culture medium of HeLa 
cells expressing wild-type hALAS2 or XLEPP variants reduces the inhibitory effect 
of INH on PPIX accumulation. Mean PPIX fluorescence values are representative of 
three separate experiments ± standard deviation (*p<0.05, Student’s t-test) [a.u., 
arbitrary units]. 
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INH inhibits purified hALAS2—Since our findings with hALAS2- and 
XLEPP-expressing mammalian cells supported the proposition that inhibition of 
hALAS2 activity by INH involves PLP depletion, we set out to determine if INH 
could directly inhibit purified hALAS2, affect the availability of PLP, or if INH 
worked through a combination of both mechanisms. In the presence of excess of 
glycine (100 mM) and succinyl-CoA (100 µM) concentrations (i.e., over 10-fold 
the Km values of the two substrates (13,27)), INH inhibited hALAS2 activity 
(Figure 4.5A), and similarly, INH inhibited the ALAS activity of delAGTG (data not 
shown). To determine if the depletion of PLP and consequent inhibition of the 
purified hALAS2 resulted from the reaction between INH and the PLP cofactor or 
a decrease in available PLP for binding to hALAS2 and formation of the active 
holoenzyme, we included an additional step involving the incubation of INH with 
PLP prior to the assay reaction. The greater Ki
app values for INH (from 2.7 to 10.6 
µM) with increased PLP concentrations (Figure 4.5B) indicated that a portion of 
the INH reacts with PLP in such a way that INH can no longer inhibit hALAS2. At 
concentrations of INH of 10 M and below, preincubation of INH with PLP 
reduced hALAS2 inhibition; however, 100 M INH caused nearly 100% activity 
loss regardless of the concentration of PLP. In addition to these experiments in 
which INH was incubated with PLP prior to mixing with hALAS2, similar 
experiments were run in which hALAS2 (1.5 µM) was incubated with INH (0-100 
µM) prior to mixing with PLP (0-40 µM) (data not shown). Regardless of the 
concentration of PLP added to the hALAS2-INH, the apparent Vmax was 
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unchanged, indicating that once INH is bound to hALAS2, PLP cannot reverse 
inhibition. 
 
INH is not a competitive inhibitor for glycine—We next investigated 
whether INH competed with the glycine substrate for binding to the active site of 
hALAS2 (Figure 4.6A-B). INH decreased the Vmax for glycine and increased the 
 
  
 
FIGURE 4.5. INH inhibits the activity of purified hALAS2. A. Percent activity loss 
values are representative of three separate experiments ± standard deviation. Data were 
fit to Equation 2. B. INH inhibition of hALAS2 occurs in part independently of PLP 
availability. Enzymatic activity was determined over a range of INH concentrations (1 – 
100 µM), at constant hALAS2 concentration (1.5 μM), and at constant PLP 
concentrations. Each data point represents the percentage activity loss either in the 
absence (blue) or in the presence of different added concentrations of PLP: 5 μM 
(green), 10μM (pink), 20 μM (cyan) and 40 μM (black). The corresponding colored 
curves are the best fits of the data to Equation 1, and the the respective estimated Ki 
values for INH are 2.7 μM, 5.1 μM, 7.5 μM, 9.7 μM and 10.6 μM. Activity loss values are 
averages of three separate experiments. 
 
Km for glycine (Figure 4.6A). The decrease in the Vmax for glycine with increased 
INH concentration indicates that INH does not compete with glycine to bind to 
hALAS2. From the secondary plot of these data fit to Equation 1, we determined 
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the apparent inhibitory constant (Ki
app) to be 1.5 M. Dynafit analysis of the 
kinetic data for INH inhibition excluded competitive and mixed inhibition, and 
supported partial inhibition of the type in Scheme 1, 
 
              (1) 
 
where E represents ALAS, S is the substrate glycine, P is the product, and I is 
INH.  The fitted parameters were 4.5 mM for the dissociation constant of glycine, 
2.0 s-1 for kcat, 0.4 s
-1 for k’cat, and 1.2 µM for the Ki
app of INH. 
We also performed similar experiments to assess competition for succinyl-
CoA binding, but the enzyme concentration was  close to that of the Km for 
succinyl-CoA (4.3 µM) (13), and the colorimetric assay was not sensitive enough 
to attain reliable signal to noise ratio at succinyl-CoA concentrations below 10 
µM. Thus, there was a high error associated with the Ki
app calculated from the 
secondary plot of these data. While the apparent Km for each concentration of 
INH could not be determined from the primary plot due to high error at succinyl-
CoA concentrations less than 10 µM, a trend of decrease in the Vmax for succinyl-
CoA as a result of increased INH concentrations was apparent (data not shown).   
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Figure 4.6. INH does not compete with glycine to bind hALAS2. A. INH 
concentrations are as follows: 0 µM (black), 2 µM (yellow), 5 µM (green), 10 µM (pink), 
and 50 µM (blue). Data were fit to Equation 4.1. B. Lineweaver-Burke reciprocal plot 
constructed using the data from primary plots. Activity values are averages of three 
separate experiments. 
 
Taken together, these findings indicate that INH inhibits hALAS2 in a dose-
dependent manner and does not directly compete for binding with either the 
glycine or succinyl-CoA substrates. 
 
The hydrazine moiety of INH is necessary, but not sufficient for complete 
ALAS2 inhibition—Previously, using UV-visible absorption spectroscopy, we 
determined that the addition of INH (100 µM) to the PLP-glycine aldimine (100 
µM PLP and 10 mM glycine) disrupted the Schiff base linkage as monitored by a 
decrease in absorbance at 420 nm (data not shown). Thus, we posited whether 
the reactive hydrazine moiety of INH would be sufficient to inhibit hALAS2. 
Pyrazinamide, an antibiotic also used to treat tuberculosis, has a similar size and 
structure to INH, but has an amide group on a pyrazine ring instead of a 
hydrazine group on a pyridine ring (Figure 4.7A, inset). To determine whether the 
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hydrazine moiety of INH was the major contributor to the inhibition of hALAS2 by 
INH, we compared the hALAS2 activity in the presence of INH, pyrazinamide, or 
1,1-dimethylhydrazine (Figure 4.7B, inset). Of significance, patients treated with 
pyrazinamide can also present anemia, which led us to hypothesize that hALAS2 
might also be inhibited by this antibiotic (13,28). We found that while both 
pyrazinamide (Figure 4.7A) and 1,1-dimethylhydrazine (Figure 4.7B) could 
reduce hALAS2 activity, neither could inhibit hALAS2 to the same level as INH 
(Figure 4.7A-B) suggesting that both the hydrazine moiety and structure of INH 
are important for complete inhibition of hALAS2. 
 
INH induces changes in the tertiary structure and PLP-binding to ALAS2—
Our activity assay data supported the hypothesis that INH can directly inhibit 
hALAS2, but it was still unclear where and how INH binds to hALAS2. Since INH 
was not a competitive inhibitor for glycine or succinyl-CoA, we hypothesized that 
INH binds at an alternate site which results in a structural rearrangement that 
lead to a diminishment in hALAS2 activity. Thus, we next examined the 
secondary and tertiary structural changes induced in hALAS2 upon binding of 
INH. CD spectroscopy revealed that while INH did not induce any major changes 
in secondary structure (data not shown). INH altered the tertiary structure of 
hALAS2 in a concentration-dependent manner, as visualized by changes in 
mean residue molar ellipticity bands at wavelengths corresponding to aromatic 
residues (260-295 nm) (Figure 4.8A). Specifically, INH decreases the tyrosine 
and tryptophan signals, which show bands between 275 and 282 nm and at 290 
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nm, respectively (29). INH also affected the visible region of the CD spectra; INH 
decreased the mean residue molar ellipticity band between 420-440 nm, which 
indicated that the orientation and positioning of PLP in the active site of hALAS2 
was disrupted by INH (13,30) (Figure 4.9B). The decrease in mean residue molar 
ellipticity exhibited an INH concentration dependence described by a hyperbolic 
curve and a value of 53 M for the INH concentration at which the mean residue 
molar ellipticity was one half of its maximal value. Similar to the activity of 
hALAS2, the structural changes induced by INH were time-dependent. Because 
we accumulated and averaged either 3 or 4 CD scans per variant, the structural 
changes within the first 30 minutes could not be distinguished. There were,  
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Figure 4.7. Pyrazinamide and 1,1-dimethylyhydrazine do not inhibit hALAS2. Wild-
type hALAS2 was incubated with INH (black), (A) pyrazinamide (pink), or (B) 1,1,-
dimethylhydrazine (blue) ranging from 0 to 100 µM before measuring ALAS activity. The 
structures for INH, pyrazinamide, and 1,1-dimethylhydrazine are provided as insets in 
each graph. Percent activity loss values are representative of three separate 
experiments ± standard deviation. 
 
 
however, slight differences between the spectra of hALAS2 obtained immediately 
after INH addition and spectra of hALAS2 incubated with INH for 24 hours (data 
not shown), that indicated a time-dependence in the structural changes.   
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The CD spectra for the delAGTG variant (Figure 4.9) differed from those 
for wild-type hALAS2 (Figure 4.8A) in both the near UV and visible regions, with 
the most obvious difference being the presence of a mean residue molar 
ellipticity band at 330 nm for delAGTG (not present in the wild-type spectrum), 
often associated with PLP bound to its protein partner in a site which confers 
chirality (13,29). Similarly to wild-type hALAS2, INH altered the tertiary structure 
of the delAGTG variant in a concentration-dependent manner (Figure 4.9A). INH 
also affected the visible region of the CD spectra dose-dependently, as noted by 
decreased mean residue molar ellipticity at the wavelengths associated with PLP 
bound in the active site of hALAS2 (330nm and 420nm) (Figure 4.9B). 
 
 
 
Figure 4.8. INH induces changes in the tertiary structure of ALAS2 and binding of 
the PLP cofactor.  (A) CD spectra in the near UV and visible region for wild-type 
hALAS2 prior to reaction with INH (cyan) and after incubation with increasing 
concentrations of INH up to 100 M (green). (B) The decrease in mean residue molar 
ellipticity at 420 nm plotted against the concentration of INH. Data were fit to Equation 
4.1. 
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FIGURE 4.9. INH induces changes in the tertiary structure of delAGTG and binding 
of the PLP cofactor. CD spectra in the near UV and visible region for delAGTG prior to 
INH addition (―), and upon the addition of 60 M INH (- - -) and 100 M INH (·····). 
 
 
 
Discussion 
Isoniazid has a long history of being used to treat tuberculosis infections, 
dating back to at least 1952 (31). Case studies reporting anemia as a common 
side effect were reported as early as 1962, and continued as doctors began 
expanding the use of isoniazid to treat tuberculosis patients (16,32-34). In some 
cases, patients recover from the acquired anemia when taken off of isoniazid, 
while others also require dietary pyridoxine supplementation to fully recover 
(16,21,34-36). In general, pyridoxine supplements are given to patients taking 
isoniazid in order to prevent onset of anemia (37). In addition to case studies in 
tuberculosis patients, the effects of INH on erythropoiesis have been 
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characterized in mice; when INH was administered during induced erythropoiesis 
in mice, heme synthesis and erythroid maturation were inhibited (38). 
INH is well-studied in patients treated for tuberculosis (14,39,40), and, in 
Mycobacterium tuberculosis, INH is known to be activated by the katG enzyme 
and subsequently to target enzymes required for mycolic acid synthesis (41-47), 
However, the mechanism by which INH causes cell death remains elusive in 
Mycobacterium tuberculosis (42), and metabolism of INH in human cells is not 
well-investigated.  Thus, in our studies, we explored the effects of INH in human 
cell lines, focusing on elucidating the mechanisms of INH-induced anemia. Our 
studies using mammalian cell cultures indicate that INH decreases PPIX 
accumulation in HeLa cells overexpressing hALAS2 (Figure 4.1), thus decreasing 
PPIX transported into surrounding cells (Figure 4.2), and demonstrate that INH is 
effective in reducing hALAS2 activity ex vivo. While pyridoxine did not lessen the 
effect of INH on PPIX levels (Figure 4.3), addition of either PLP or PMP 
completely reversed the effects of INH (Figure 4.4).  
 The results of these initial experiments might be interpreted by using the 
known PLP-dependent mechanisms of hALAS2 inhibition by INH, in which INH 
inhibits pyridoxal kinase (17,18), the enzyme that produces PLP, and also reacts 
with PLP to form pyridoxal isonicotinoyl hydrazones (19,20). However, it was still 
unclear if INH had a more direct effect on hALAS2 activity that would better 
explain the specific side effect of sideroblastic anemia. In order to reduce the 
number of variables, we began in vitro experiments in which we could more 
stringently control the experimental conditions. In doing so, we found that INH 
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inhibits purified hALAS2 regardless of the presence of excess PLP (Figure 4.5B). 
Excess PLP in the reaction buffer did affect the apparent Ki values for INH, 
indicating that a small percentage of the INH might have reacted with PLP to 
form pyridoxal-hydrazones (20), thus reducing the amount of INH available to 
inhibit hALAS2. However, 100 M INH caused nearly 100% activity loss 
regardless of the concentration of PLP (Figure 4.5B), suggesting a PLP-
independent mechanism of hALAS2 inhibition by INH. We subsequently found 
that INH is not a competitive inhibitor for either the glycine or succinyl-CoA 
substrates, as it decreases the Vmax and increases the Km values for glycine, and 
decreases the Vmax for succinyl-CoA. These data suggest that INH binds to an 
alternate site distinct from the glycine-binding site and decreases the affinity of 
hALAS2 for glycine.  
Other antibiotic drugs commonly prescribed to treat tuberculosis, such as 
pyrazinamide, chloramphenicol, and cycloserine, have also been associated with 
drug-induced sideroblastic anemia (6,48). However, it has been noted that some 
patients treated with a cocktail of antibiotics for tuberculosis can recover from 
sideroblastic anemia by withdrawal of only INH from the cocktail (14). Since the 
ability of pyrazinamide to induce sideroblastic anemia in patients is unresolved 
(14,28,48), we examined whether pyrazinamide similarly affected hALAS2 
activity. Pyrazinamide did not inhibit hALAS2 activity at concentrations below 30 
µM, whereas 30 µM INH resulted in greater than 80% inhibition of hALAS2 
activity (Figure 4.7). Structural comparison of INH and pyrazinamide suggested 
that the hydrazine moiety of INH might be important for the inhibition of hALAS2. 
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In order to ascertain if hydrazine was sufficient to react with and inhibit hALAS2, 
we used 1, 1-dimethylhydrazine in our activity assay. At concentrations below 10 
µM, 1,1-dimethylhydrazine resulted in modest activity loss, but even at 
concentrations up to 500 µM, activity loss never reached 50%. Thus, both the 
hydrazine moiety and the linkage of the hydrazine moiety on the pyridine ring of 
INH appear crucial for complete inhibition of hALAS2.  
The chemical mechanism of ALAS2 begins, in the absence of substrates, 
with active site lysine 313 of ALAS2 bound to PLP forming an internal aldimine 
(Figure 4.10). In the presence of substrates, the glycine binds first, followed by 
transaldimination with the active site lysine to yield an external aldimine (49). 
Next, the pro-R proton of glycine is abstracted by the active site lysine, followed 
by condensation with succinyl-CoA and CoA release to generate an α-amino-β- 
ketoadipate intermediate. This step is followed by decarboxylation resulting in an 
enol-quinonoid rapid equilibrium, then protonation of the enol to give an aldimine-
bound molecule of ALA, and ultimately release of the product (ALA) (49). Despite 
the complexity of the proposed chemical mechanism, transient kinetic studies 
have led investigators to propose that the rate-determining step of the ALAS-
catalyzed reaction is product release or a conformational change leading to 
product release (49,50). It is the movement of the active site loop (51) towards 
the open conformation that controls the rate at which ALA dissociates, and 
therefore the overall catalytic rate (30,49,50,52,53). Since INH does not compete 
with the substrates, one possibility is that binding of INH stabilizes the closed 
conformation of hALAS2. INH could bind both the hALAS2 holoenzyme and 
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FIGURE 4.10. Chemical mechanism of the ALAS2-catalyzed reaction. (I) ALAS2 
internal aldimine, (II) glycine-ALAS2 external aldimine, (III) quinonoid intermediate I, (IV) 
glycine-succinyl-CoA condensation intermediate, (V) α-amino-β-ketoadipate 
intermediate, (VI) enol intermediate, (VII) quinonoid intermediate II, (VIII) ALA-ALAS2 
external aldimine. 
 
 
glycine-bound hALAS2, which is consistent with the Dynafit prediction of partial 
inhibition (Scheme 1). 
To better resolve the mechanism of inhibition, we examined the possibility 
of secondary and tertiary structural changes associated with binding of INH to 
hALAS2. We could not delineate significant secondary structural changes, but 
the tertiary structure exhibited a distinct, concentration-dependent change upon 
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incubation with INH. The changes in fluorescence of the aromatic residues of 
hALAS2 as seen in these CD spectra (Figure 4.8A) indicate that INH elicits a 
protein conformational change that renders the enzyme either less active or 
inactive. CD spectroscopy also revealed a concentration-dependent decrease in 
the mean residue molar ellipticity band between 420-440 nm, indicating that INH 
disrupts the hALAS2-PLP bond, apparently yielding an enzyme devoid of the 
Schiff base linkage (Figure 4.8A-B). Decreased PLP-binding of ALAS2 has been 
noted previously with mouse ALAS2 when serine 254 was mutated to an alanine 
residue (30). This active site mutation causes a change in the microenvironment 
of the PLP cofactor and disrupts the binding of succinyl-CoA (30). We also 
observed changes in tertiary structure and PLP-binding with the XLEPP variant 
delAGTG (Figure 4.9). One possibility is that INH causes a structural change that 
inhibits PLP binding, following either direct displacement or remote binding.  This 
could explain why excess PLP cannot completely reverse activity loss caused by 
INH in vitro. In the cellular environment, ALAS2 is peripherally associated with 
the mitochondrial membrane and is known to bind at least one other enzyme 
partner, succinyl-CoA synthetase (12,54). INH might not bind as tightly or 
displace PLP as effectively when ALAS2 is membrane- and/or protein-bound, 
which might explain why PLP can reverse the INH inhibition ex vivo (21).  
Here we provide evidence that INH directly inhibits purified hALAS2. Our 
data suggest that INH is an inhibitor that affects the functionality of the PLP 
cofactor. We propose a mechanism by which addition of INH to hALAS2 results 
in structural rearrangement of the protein and disruption in the hALAS2-PLP 
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linkage, thus inhibiting hALAS2 activity. To determine the position and location at 
which INH binds to hALAS2, further studies including x-ray crystallization of 
hALAS2 with INH are warranted. These data provide support for using INH to 
treat cutaneous porphyrias, especially for XLEPP, where hALAS2 is overly 
active. The direct effect of INH on hALAS2 activity should also be considered 
when treating tuberculosis patients who have developed sideroblastic anemia. 
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CHAPTER 5: SUMMARY AND CONCLUSION 
 
 
This dissertation focuses on mutations in ALAS2 that lead to an increased 
activity of the enzyme. ALAS2 can be used to produce the heme precursor PPIX, 
which is used as a photosensitizer for PDT. Thus mutations in ALAS2 that 
increase its activity offer a means to increase PPIX photosensitization. We 
explored mutations located in the presequence known to alleviate the heme 
feedback inhibition of ALAS2 translocation into the mitochondrion (1) and 
mutations in the active site loop region known to increase ALAS2 activity (2,3), 
and assessed the ability of the ALAS2 variants to accumulate PPIX in 
mammalian cells and cause light-induced cell death. In humans, hALAS2 
mutations in the C-terminus can result in increased activity and are associated 
with XLEPP. We characterized mutations in the hALAS2 C-terminus associated 
with XLEPP using purified recombinant hALAS2 and ex vivo in mammalian cells 
in terms of their catalytic activity, substrate affinities, thermostability, cellular 
activity, and structure. Since there are no specific treatments for XLEPP as of 
yet, we evaluated the use of a potential drug, INH, to treat XLEPP by inhibiting 
hALAS2. The conclusions presented add to the general knowledge of the 
ALAS2-catalyzed reaction, further elucidate the mechanism of XLEPP, and 
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provide evidence for isoniazid as an inhibitor of hALAS2, which has potential for 
treating porphyria patients. 
 To restrict photosensitivity by biological, rather than just chemical or 
physical means, we emulated an idea set forth by Gagnebin et al. (4) to deliver 
ALAS to tumors for PDT not only for better targeting, but also for greater 
photosensitivity (4). We used more highly active variants of mALAS2 (2,3) and 
postulated that these variants would increase PPIX accumulation, phototoxicity, 
and targeted cell death sufficiently to make the approach more clinically 
attractive. The HeLa cells that accumulated the highest amount of PPIX were 
those expressing R433K, an mALAS2 variant with mutated HRMs and the 
arginine residue at position 433 in the active site loop mutated to a lysine. 
Expression of R433K in HeLa cells produced a 2- to 3-fold increase in PPIX in 
comparison to WT, and a 4- to 6-fold increase in PPIX fluorescence in 
comparison to cells transfected with the pIRES2-ZsGreen1 vector control or 
HeLa cells alone. When the culture medium was supplemented with glycine, 
PPIX accumulation increased by 13- to 15-fold in comparison to cells transfected 
with the pIRES2-ZsGreen1 vector control or HeLa cells alone, and represented 
the conditions for the highest cellular PPIX accumulation. To study the 
photosensitivity of cells that accumulated PPIX, we performed light treatments 
using an incandescent lamp, which emits light in the visible and infrared spectral 
regions (400-1000 nm). The highest cell death of up to 90% was seen in light-
treated HeLa cells expressing ZsGreen1 and R433K, in culture medium 
supplemented with 100 mM glycine. This represents a substantial improvement 
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over the 26% cell death reported previously (4), and indicates that this approach, 
if carefully developed, may eventually find some clinical utility.  
Next we studied mutations in the C-terminus of hALAS2 associated with 
XLEPP that cause an increase in activity. Much like in XLSA, whereby multiple 
molecular mechanisms can contribute to a decrease in hALAS2 activity, we show 
that the XLEPP variants differ from wild-type and each other in their substrate 
affinities, thermostability, secondary structure upon substrate binding, tertiary 
structure, and integrity of the PLP-binding site. Kinetic analyses performed with 
purified recombinant hALAS2 variants at 37°C revealed that delAT, in 
comparison to wild-type hALAS2, exhibited a reduced catalytic efficiency for 
glycine, but the efficiency for succinyl-CoA was unaffected. DelAGTG exhibited 
increased catalytic efficiency for both substrates in comparison to wild-type, and 
Q548X had only a slight increase in catalytic efficiency for succinyl-CoA. While 
wild-type hALAS2 exhibited a sharp decrease in activity as the temperature 
increased from 45°C to 55°C, the decrease in activity for the variants was less 
abrupt and low levels of activity persisted up to 70°C. The purified XLEPP 
variants are more stable at temperatures above 55°C, indicating that the variants 
also have increased stability independent of interaction with SCS and resistance 
to proteolysis. These results led us to examine the structures of purified wild-type 
hALAS2 and the XLEPP variants. 
The far-UV CD spectra for hALAS2 and the variants are dominated by α-
helical structure, and are similar among the variants. However, upon addition of 
succinyl-CoA, the XLEPP variants exhibit a change in secondary structure that is 
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not evident with the wild-type enzyme. These CD spectra imply the possibility 
that a structural change that occurs upon binding of succinyl-CoA could be the 
reason behind the increased affinities of the XLEPP variants for succinyl-CoA. 
Each variant has a distinct near-UV CD spectrum that differs in intensity and 
shape from the wild-type enzyme, indicating that the positioning of the aromatic 
amino acids is altered in the XLEPP variants. The CD signals in the visible 
spectral region are excellent indicators of the integrity of the PLP cofactor-binding 
site (5) because, as with other PLP-dependent enzymes (6,7), absorption 
maxima at 330 and 420 nm are characteristic of different ionization states of the 
internal aldimine bond between the PLP and the ALAS, corresponding to the 
unprotonated and protonated forms, respectively (2,8). The binding of delAGTG 
and Q548X to PLP display slightly higher intensity bands between 420-430 nm, 
but exhibit large bands around 330 nm that are not evident in wild-type or delAT 
CD spectra. PLP appears to bind these variants more tightly, and specifically in 
both ionization states. Upon addition of succinyl-CoA, the band associated with 
the unprotonated internal aldimine for delAGTG and Q548X shifts to the right to 
become a broader band from 340-400 nm, indicating a change in the chirality of 
PLP in the active site when succinyl-CoA is bound. These studies are the first 
structural studies of the XLEPP variants of hALAS2 and they offer a new 
perspective to what is known about the molecular mechanism behind XLEPP. 
We provide evidence that XLEPP can be modeled in cell culture, and this model 
may aid in testing for direct action of potential therapeutics on hALAS2. We also 
found that the XLEPP variants are more thermostable, undergo distinct 
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conformational changes upon the addition of substrate, and differ in tertiary 
structure and PLP binding.  
Using our developed cell culture model of XLEPP and purified 
recombinant proteins, we then explored the effects of INH, focusing on 
elucidating the mechanisms of INH-induced anemia and evaluating potential for 
XLEPP drug therapy. Our studies using mammalian cell cultures indicate that 
INH decreases PPIX accumulation in HeLa cells overexpressing hALAS2, and 
demonstrate that INH is effective in reducing hALAS2 activity ex vivo. While 
pyridoxine did not lessen the effect of INH on PPIX levels, addition of either PLP 
or PMP completely reversed the effects of INH. The results of these initial 
experiments might be interpreted by using the known PLP-dependent 
mechanisms of hALAS2 inhibition by INH, in which INH inhibits pyridoxal kinase 
(9,10), the enzyme that produces PLP, and also reacts with PLP to form 
pyridoxal isonicotinoyl hydrazones (11,12), but do not rule out the possibility of 
direct inhibition of hALAS2 by INH. We next used purified hALAS2 to test 
whether INH could directly inhibit hALAS2, and found that INH inhibits purified 
hALAS2 regardless of the presence of excess PLP. Excess PLP did, however, 
affect the apparent Ki values for INH, indicating that a small percentage of the 
INH might have reacted with PLP to form pyridoxal-hydrazones (12), thus 
reducing the amount of INH available to inhibit hALAS2. However, 100 M INH 
caused nearly 100% activity loss regardless of the concentration of PLP, 
suggesting a PLP-independent mechanism of hALAS2 inhibition by INH. We 
subsequently found that INH is not a competitive inhibitor for either the glycine or 
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succinyl-CoA substrates, as it decreases the Vmax and increases the Km values 
for glycine, and decreases the Vmax for succinyl-CoA. These data suggest that 
INH binds to an alternate site that is distinct from the glycine-binding site, and 
decreases the affinity of hALAS2 for glycine. Additionally, by evaluating the 
inhibitory effects of pyrazinamide and 1,1-dimethylhydrazine, we concluded that 
both the hydrazine moiety and the linkage of the hydrazine moiety on the pyridine 
ring of INH are crucial for complete inhibition of hALAS2.  
Given that INH does not compete with the substrates, one possibility is 
that binding of INH stabilizes the closed conformation of hALAS2. INH could bind 
both the hALAS2 holoenzyme and glycine-bound hALAS2, which is consistent 
with partial inhibition of the enzyme. To better resolve the mechanism of 
inhibition, we examined the possibility of structural changes associated with 
binding of INH to hALAS2. The changes in fluorescence of the aromatic residues 
of hALAS2, as seen in CD spectra, indicate that INH elicits a protein 
conformational change that renders the enzyme either less active or inactive. CD 
spectroscopy also revealed a concentration-dependent decrease in the mean 
residue molar ellipticity band between 420-440 nm, indicating that INH disrupts 
the hALAS2-PLP bond, apparently yielding an enzyme devoid of the Schiff base 
linkage. Decreased PLP binding of ALAS2 has been noted previously with 
mouse ALAS2 when serine 254 was mutated to an alanine residue (13). This 
active site mutation causes a change in the microenvironment of the PLP 
cofactor and disrupts the binding of succinyl-CoA (13). Our data suggest that INH 
is an inhibitor of hALAS2 that affects the functionality of the PLP cofactor. We 
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propose a mechanism by which addition of INH to hALAS2 results in structural 
rearrangement of the protein and disruption in the hALAS2-PLP linkage, thus 
inhibiting hALAS2 activity. To determine the position and location at which INH 
binds to hALAS2, further studies including x-ray crystallization of hALAS2 with 
INH are warranted. These data provide support for using INH to treat cutaneous 
porphyrias, especially for XLEPP, where hALAS2 is overly active. The direct 
effect of INH on hALAS2 activity should also be considered when treating 
tuberculosis patients who have developed sideroblastic anemia.  
In conclusion, this body of work explores mutations in ALAS2 that cause 
increased PPIX from two different perspectives. Firstly, we investigated 
mutations to be utilized as tools for developing ALAS-PDT, and found that 
mutation of the HRMs, in combination with the R433K mutation, results in 
significant cellular PPIX accumulation and up to 90% cell death upon light 
treatment. Secondly, we studied mutations in hALAS2 associated with the 
disease XLEPP, and elucidated structural changes that help to explain how the 
C-terminal mutations result in changes in catalytic activity of hALAS2, which in 
turn produce the symptoms of XLEPP. Furthermore, we presented INH as an 
inhibitor of hALAS2 and a promising therapy for XLEPP patients.  
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